

Quality of Diagnostic Samples

Recommendations of the Working Group on Preanalytical Quality of the German Society for Clinical Chemistry and Laboratory Medicine

W.G.Guder, F. da Fonseca-Wollheim, W. Heil, Y. Schmitt, G. Töpfer, H. Wisser, B. Zawta (†)

Corresponding members and industry representatives :

Carmen Alf, Recipe Chemicals and Instruments, Munich, Germany	H. Kitta, Klinika GmbH, Usingen, Germany
G. Banfi, Milan, Italy	Daniela Klahr, Andreas Hettich GmbH, Tuttlingen, Germany
K. Bauer, Vienna, Austria	D. Kolpe, Kabe Labortechnik GmbH, Nümbrecht-Elsenroth, Germany
W. Brand, Sarstedt, Nümbrecht, Germany	J. Kukuk, Rolf Greiner Biochemica, Limburg, Germany
M. Buchberger, C.A. Greiner, Kremsmünster, Austria	Tamara Kunert-Latus, Terumo Europe, Leuven, Belgium NV
S. Church, BD Diagnostics, Europe, Oxford, England	M. Lammers, Patrizia Mikulcik, Siemens Healthcare Diagnostics, Marburg and Eschborn, Germany
A. Deom, Geneva, Switzerland	E.A. Leppänen, Helsinki, Finland
V. Ehrhardt, Roche Diagnostics GmbH, Mannheim, Germany	S. Naryanan, New York, USA
G.M. Fiedler, Leipzig, Germany	M. Neumaier, Mannheim, Germany
C.G. Fraser, Dundee, Scotland	Maria Adelina Peça Gomes, Lisbon, Portugal
S. Golf, Giessen, Germany	K.-H. Pick, Abbott GmbH, Wiesbaden, Germany
H. Gross, Kendro Laboratory Products, Hanau, Germany	Antje Piening, Beckmann-Coulter, Nyon, Switzerland
G. Gunzer, Beckmann-Coulter, Olympus, Munich, Germany	R. Probst, Olching, Germany
P. Hagemann, Zürich, Switzerland	Elke Rauhut, DiaSorin, Dietzenbach, Germany
H. Hallander, Solna, Sweden	Carmen Ricos, Barcelona, Spain
N. Hamasaki, Fukuoka, Japan	Kathrin Schlüter, BD Diagnostics, Heidelberg, Germany
J. Henny, Vandoeuvre - lès - Nancy, France	O. Sonntag, Ortho Clinical Diagnostics, Neckargemünd, Germany
R. Hinzmann, Sysmex-Europe, Norderstedt, Germany	D. Young, Philadelphia, USA
G. Hoffmann, Trillium, Grafrath, Germany	
P. Hyltoft Petersen, Odense, Denmark	
A. Kallner, Stockholm, Sweden	

Quality of Diagnostic Samples

Recommendations of the Working Group on Preanalytical Quality of the German Society for Clinical Chemistry and Laboratory Medicine



Helping all people
live healthy lives

- Plasma, serum or whole blood?
- Choice of anticoagulant
- The optimal sample volume
- Stability during transport and storage of samples
- The haemolytic, lipaemic and icteric sample



Contens

1. INTRODUCTION	5
2. Serum, Plasma or Whole Blood? Which Anticoagulants to Use?	8
2.1 Definitions	8
2.2 Plasma or serum?	9
2.3 Recommendations	10
3. The Optimal Sample Volume	13
3.1 Definition	13
3.2 Recommendations	13
3.3 Measures which can help to reduce the required blood volume	14
3.4 Documentation	14
4. Analyte Stability in Sample Matrix	16
4.1 Stability and instability	16
4.2 Quality assurance of the time delay during the preanalytical phase	17
5. The Haemolytic, Icteric and Lipaemic Sample	18
5.1 Definition of a clinically relevant interference	18
5.2 General recommendations	19
5.3 The haemolytic sample and the effect of therapeutic haemoglobin derivatives	20
5.4 The lipaemic sample	24
5.5 The icteric sample	28
6. Samples and Stability of Analytes	32
6.1 Blood	32
6.2 Urine	66
6.3 Cerebrospinal fluid (CSF)	68
7. References	70

1. Introduction

It is imperative that the in vivo state of a constituent remains unchanged after withdrawal of the body fluid from a patient to obtain a valid medical laboratory result. This may not always be possible when measuring extracellular and cellular components of blood. Platelets and coagulation factors are activated when blood vessels are punctured, and their activation continues in sample containers that do not contain anticoagulant.

Historically, serum was the preferred assay material for determining extracellular concentrations of constituents in blood. Today, plasma is preferred for many, but not all laboratory investigations because the constituents in plasma are better at reflecting the pathological situation of a patient than those in serum. Some changes of constituents can be avoided by using anticoagulants. The types and concentrations of anticoagulants used in venous blood samples were defined in the international standard (117) in 1996. The standardised anticoagulants are now used to prepare standardised plasma samples for laboratory investigations throughout the world.

This document summarises the findings published in the literature and those observed by the contributors on the use of anticoagulants. The overview was prepared in collaboration with experts from clinical diagnostic laboratories and the diagnostics industry (94-97), recently published in German in its 6th edition (98).

In the meantime, this work was confirmed by several international publications. After Bonini et al. (25) concluded from the existing literature that 50 -75 % of laboratory errors appear in the preanalytical phase, this part of medical laboratory became increasingly important in literature and daily practice. Thus Fiedler and Thiery (67,252) showed that interpretation of laboratory results leads to false conclusions due to preanalytical errors. Contributions to the preanalytical phase to results in coagulation testing (20, 174), tumor marker diagnostics (4), cardiac markers (17) and therapeutic drug monitoring (244) express the importance of including this phase in quality assurance programmes. Experience during laboratory accreditation procedures also confirmed the importance which has been included into the ISO EN, DIN standard 15 189 on quality and competence requirements in medical laboratories (118).

This standard includes requirements and advice regarding preanalytical quality under chapter

5.4 : Pre examination procedures

5.4.1 The request form shall contain information sufficient to identify the patient and the authorised requester, as well as providing pertinent clinical data. National, regional or local requirements shall apply.

The request form, or an electronic equivalent, should allow space for the inclusion of, but not be limited to, the following:

- unique identification of the patient ;
- name or other unique identifier of physicians or other persons legally authorized to request examinations or use medical information together with the destination for the report. The requesting clinician's address should be provided as part of the request form information when it is different from that of the receiving laboratory.
- type of primary sample and the anatomic site of origin, where appropriate;
- examinations requested;
- clinical information relevant to the patient, which should include gender and date of birth, as a minimum, for interpretation purposes;
- date and time of primary sample collection;
- date and time of receipt of samples by the laboratory.

5.4.2 Specific instructions for the proper collection and handling of primary samples shall be documented and implemented by laboratory management and made available to those responsible for primary sample collection. These instructions shall be contained in a primary sample collection manual.

5.4.3 The primary sample collection manual shall include the following:

- Copies or references to
 - lists of available laboratory examinations offered,
 - consent forms, when applicable,
 - informations and instructions provided to patients in relation to their own preparation before primary sample collection, and
 - information for users of laboratory services on medical indications and appropriate selection of available procedures;
- Procedures for:
 - preparation of the patient (e.g. instructions to care givers and phlebotomists),
 - identification of primary sample, and
 - primary sample collection (e.g. phlebotomy, skin puncture, blood, urine and other body fluids), with description of the primary sample containers and necessary additives;
- Instructions for
 - completion of request form or electronic request,
 - type and amount of primary sample to be collected;
 - special timing of collection, if required,
 - any special handling needs between time of collection and time received by the laboratory(transport requirements, refrigeration, warming, immediate delivery etc.),
 - labelling of primary samples,
 - clinical information (e.g. history of administration of drugs) ,
 - positive identification, in detail, of the patient from whom the primary sample is collected,

- recording the identity of the person collecting the primary sample,
 - safe disposal of materials used in the collection;
- d) Instructions for
- storage of examined samples ,
 - time limits for requesting additional examination,
 - additional examinations, and,
 - repeat examinations due to analytical failure or further examinations of same primary sample".

The following texts describe detailed advice regarding transport and storage of primary tubes:

5.4.14: Samples shall be stored for a specified time, under conditions ensuring stability of sample properties, to enable repetition of the examination after reporting of the results or for additional examinations."

These processes have become part of national and international quality management and -assurance procedures and are increasingly used during certification and accreditation procedures. They became part of the directives of the Federal Medical Association (Bundesärztekammer) in 2008 (204).

The authors hope that the included recommendations developed over many years can contribute to the improvement of medical laboratory results and thereby help provide patients with better treatment.

2. Serum, Plasma or Whole Blood? Which Anticoagulants to Use?

2.1 Definitions

Whole blood

A venous, arterial or capillary blood sample in which the concentrations and properties of cellular and extracellular constituents remain relatively unaltered when compared with their in vivo state. Anticoagulation in vitro stabilises the constituents in a whole blood sample for a certain period of time.

Plasma

The virtually cell-free supernatant of blood containing anticoagulant obtained after centrifugation.

Serum

The undiluted, extracellular portion of blood after adequate coagulation is complete.

Anticoagulants

Additives that inhibit blood and/or plasma from clotting to ensure that the constituents to be measured are not significantly changed prior to the analytical process. Anticoagulation occurs by binding calcium ions (EDTA, citrate) or by inhibiting thrombin activity (heparinates, hirudin). The following solid or liquid anticoagulants are mixed with blood immediately during sample collection:

EDTA

Salts of ethylene diamine tetraacetic acid. Dipotassium (K_2), tripotassium (K_3) and disodium (Na_2) salts are used (13, 87, 117); concentrations: 1.2 to 2.0 mg/mL blood (4.1 to 6.8 mmol/L blood) based on anhydrous EDTA. The ICSH recommends K_2 -EDTA for haematological investigations (115).

Citrate

Trisodium citrate with 0.100 to 0.136 mol/L citric acid. Buffered citrate with pH 5.5 to 5.6; 84 mmol/L trisodium citrate with 21 mmol/L citric acid. 0.109 mol/L (3.2%) was recommended to reach international standardisation (38,117). Because differences were noticed between 3.2% and 3.8% (v/v) citrate when reporting results in INR (1, 38,281), WHO and CLSI recommend 0.109 mol/L (3.2%) citric acid (38,117).

A mixture of one part citrate with nine parts blood is recommended for coagulation tests (38, 117).

One part citrate mixed with four parts blood is recommended to determine the erythrocyte sedimentation rate (117).

Heparinates

12 to 30 IU/mL of unfractionated sodium, lithium or ammonium salt of heparin with a molecular mass of 3 to 30 kD is recommended to obtain standardised heparinised plasma (117).

Calcium-titrated heparin at a concentration of 40 to 60 IU/mL blood (dry heparinisation) and 8 to 12 IU/mL blood (liquid heparinisation) is recommended for the determination of ionized calcium (24, 29). Similar recommendations exist regarding ionized magnesium (21).

Hirudin

Hirudin is an antithrombin extracted from leeches or prepared by a genetic engineering process. Hirudin inhibits thrombin by forming a 1:1 hirudin-thrombin complex. Hirudin is used at a concentration of 10 mg/L (58). It was tested to replace other anticoagulants as universal anticoagulant (169).

The **colour codes** of anticoagulants are presently not standardised:

EDTA = lavender or red;

citrate 9 + 1 = light blue or green;

citrate 4 + 1 = black or mauve;

heparinate = green or orange;

no additives (for serum) = red or white.

Additional colours are used for different additives (e.g. grey for glycolysis inhibitors) such as CTAD (citrate, theophylline, adenosine, dipyridamol) and separator gels. This is to be considered when tubes from different producers are used.

2.2 Plasma or serum?

Advantages of using plasma

The following aspects support the preferential use of plasma versus serum in laboratory medicine:

Time saving: Plasma samples can be centrifuged directly after sample collection, unlike serum, in which coagulation is completed after 30 minutes,

Higher yield: 15 to 20 % more in volume of plasma than of serum can be isolated from the same volume of blood.

Prevention of coagulation-induced interferences: Coagulation in primary and secondary tubes that were already centrifuged, may block suction needles of the analysers when serum tubes are used. This is prevented by using anticoagulants.

Prevention of coagulation-induced influences: The coagulation process changes the concentrations of numerous constituents of the extracellular fluid beyond their maximum allowable limit (99, 271). The changes are induced by the

following mechanisms:

- a. Increase in the concentrations of platelet components in serum as compared to plasma (e.g. potassium, phosphate, magnesium, aspartate aminotransferase, lactate dehydrogenase, serotonin, neurone-specific enolase, zinc). Release of amide-NH₃ from fibrinogen induced by action of clotting factor XIII.
- b. Decrease in the concentration of constituents in serum as a result of cellular metabolism and the coagulation process (glucose, total protein, platelets).
- c. Activation of the cell lysis of erythrocytes and leukocytes in non-coagulated blood (cell-free haemoglobin, cytokines, receptors).

Certain constituents should only be measured in plasma (e.g. neurone-specific enolase, serotonin, ammonia) to obtain clinically relevant results.

Disadvantages of plasma over serum

The addition of anticoagulants may interfere with certain analytical methods or change the concentration of the constituents to be measured:

- a. Contamination with cations: NH₄⁺, Li⁺, Na⁺, K⁺.
- b. Assay interference caused by metals complexing with EDTA and citrate (e.g. inhibition of alkaline phosphatase activity by zinc binding, inhibition of metallo-proteinases, inhibition of metal-dependent cell activation in function tests, binding of calcium (ionized) to heparin (24)).
- c. Interference by fibrinogen in heterogeneous immunoassays (271).
- d. Inhibition of metabolic or catalytic reactions by heparin: e.g., Taq polymerase in the polymerase chain reaction (PCR) (181).
- e. Interference in the distribution of ions between the intracellular and extracellular space (e.g. Cl⁻, NH₄⁺) by EDTA, citrate (99).
- f. Serum electrophoresis can be performed only after pre-treatment to induce coagulation in plasma.

2.3 Recommendations

Table 6.1 indicates sample types that are recommended for a specific test. The table also contains information on the utility of other sample materials as long as the results measured by that method do not exceed the maximum allowable deviation of measurement (204) as defined by the biological variation (205). A maximum deviation of 10 % is assumed as being acceptable for a constituent if deviation of measurement is not defined (58).

Sample collection and transport time

The following sequence for filling tubes with blood from a patient is recommended to avoid contamination (99), modified for plastic tubes in 2007 (40):

1. blood for blood culture,
2. citrate 1+ 9 for coagulation tests,
- 2a. citrate 1+ 4 for blood sedimentation rate,
3. serum tube with no additive (avoid serum as first tube when electrolytes will be measured (154)),
- 3a. serum with gel and/or coagulation activator,
4. heparinate – plasma tube without gel separator,
- 4a. heparinate- plasma with gel separator tube,
5. EDTA tubes for haematology tests,
6. tubes containing additional stabilisers (e.g. glycolytic inhibitors),
7. trace element tube and other special tubes.

Only the recommended quantity of anticoagulant should be added, wherever required, to avoid errors in results.

Tilt the tube repeatedly (3-4 times with citrate, 5-6 times with serum, 8-10 times with sedimentation rate, heparinate and other tubes, do not shake and avoid foaming) immediately after filling to mix the sample thoroughly with the anticoagulant. Leave the containers at room temperature for at least 30 minutes to separate serum from blood cells in blood that was taken from non-anticoagulated patients. This period is shorter when coagulation has been activated. Leave the sample at room temperature no longer than the period indicated in the table (see 6.1).

Centrifugation

Blood cells are rapidly separated from plasma/serum by centrifugation at increased relative centrifugal force (rcf). Rcf and rotations per minute (rpm) are calculated using the rotating radius *r* (the distance between the axis of rotation and the base of the container in mm) by the following equation:

$$rcf = 1,118 \times r \text{ (rpm/1000)}^2$$

Centrifuge blood containers in 90°-swing-out rotors so that the sediment surface forms a right angle with the container wall. This helps to prevent contact between the sampling needle and the surface of the cell layer or separating gel in the tube, when the centrifuged blood containers are directly transferred to an analyser for analysis. When plasma coagulation is complete, centrifuge the sample for at least 10 minutes at a minimum relative centrifugal force of 1500 *g*.

Centrifuge the anticoagulated blood (citrate, EDTA or heparinised blood) for at least 15 minutes at 2000 to 3000 *g* to obtain cell-free plasma (99).

When separating serum or plasma, the temperature should not drop below 15 °C or exceed 24 °C.

Storage

Non-centrifuged samples should be stored at room temperature for the time specified in the recommendations for stability (see table 6.1). After centrifugation, the serum or plasma should be analysed within the time as recommended for whole blood, if the sample is stored without using a separating gel (82) or a filter separator in primary tubes. When the sample will be refrigerated or frozen for preservation, blood cells must first be separated from serum or plasma. Do not freeze whole blood samples before or after centrifugation, even when polymer separating gels are used.

Evaluation of new analytical procedures

Before using a new reagent or method, examine the suitability of the procedure by comparing the results of at least 20 blood samples with normal, and 20 with pathological concentrations of the constituent to be measured. The criteria for biological and clinical interpretation (reference intervals, clinical decision limits) may have to be changed, if the mean of the difference between the samples tested deviates by more than the maximum deviation allowed (204) (alternatively by more than 10 %).

3. The Optimal Sample Volume

The progress in the development of laboratory analysers has led to a reduction of the sample volume for analysis. The development, however, is not necessarily accompanied by an adaptation of sample tubes and therefore often excessive sample volumes are collected. Studies revealed (46) that 208 mL blood for 42 tests is taken during an average stay of a patient in a department of internal medicine. In intensive care the total volume drawn for 125 tests was 550 mL of blood. Previous publications describe that in half of the patients who received blood transfusion, more than 180 mL of blood were taken for laboratory tests (235). "Iatrogenic anaemia" caused by excessive blood sampling is a well-known phenomenon in paediatrics (52), whereas iatrogenic anaemia is hardly recognized as an important phenomenon in the acute and intensive care of adult patients. The following recommendations were made for sampling reduced blood volumes for analysis (95):

3.1 Definition

The amount of sample needed for laboratory diagnostic purposes (Vol b) is defined by:

1. The analytical sample volume (Vol a),
2. The dead-space volume of the analyser (Da), measured as mL plasma/serum,
3. The dead-space volume of the primary sample tube (Dp), measured as mL blood,
4. The dead-space volume of secondary sample tubes (Ds), measured as mL plasma/serum,
5. The amount of sample needed for the number (N) of repetitive analyses and additional follow-up tests,
6. The plasma sample yield according to the respective haematocrit.

Assuming that plasma/serum yield is 50 % of blood volume the total blood needed can be calculated as follows:

$$\text{Vol b} = 2 \times (N \times (\text{Vol a} + \text{Da}) + \text{Ds}) + \text{Dp}$$

3.2 Recommendations

Assuming a haematocrit of 0.50 and a need for a repetition and follow-up of laboratory tests, four times the analytical sample volume can be considered to be sufficient when plasma or serum will be used. The following standard blood volumes are recommended for analysis using advanced analytical systems. These volumes may be sufficient in 95 % of cases to provide the laboratory results as requested:

- Clinical chemistry: 4 – 5 mL (when using heparin plasma: 3 – 4 mL)
- Haematology: 2 – 3 mL EDTA blood
- Coagulation tests: 2 – 3 mL citrated blood
- Immunoassays including proteins etc: 1 mL whole blood for 3 – 4 immunoassays
- Erythrocyte sedimentation rate: 2 – 3 mL citrated blood
- Blood gases: capillary sampling: 50 µL, arterial or venous sampling: 1 mL heparin blood

The request form for laboratory analyses should include clear information on the required sample volumes and tubes. Tubes of uniform size with different filling volumes should be used. The length of the tubes should be at least four times the tube diameter. These criteria are met by standard tubes of 13 x 75 mm (diameter x length).

3.3 Measures which can help to reduce the required blood volume

- Introduction of primary tube reading in analyzers
- Deletion of sample distribution into secondary tubes
- Use of tubes with smaller diameter
- Use of analysers requiring a smaller analytical sample volume
- Storage of samples in primary tubes, using separators for plasma or serum
- Use of plasma instead of serum

3.4 Documentation

1. Any method description should include the required analytical sample volume.
2. A quality manual should document the requested sample volumes and their handling procedure.
3. The manual should describe the procedures on how to handle patient samples that have an insufficient sample volume.

It is to be expected, that by following these recommendations, together with optimal organization and collaboration with all sending persons, the size of samples can be significantly reduced. In a publication by Wisser et al (280) the real blood loss per patient following these recommendations was reported for 8 different medical disciplines. The following table summarizes the data obtained during a complete hospital stay:

Medical Department	Patient number	total blood loss (mL)	blood loss per day (mL)	number of blood drawings	number of tests ordered	blood loss during intensive care treatment (mL)
Visceral surgery	473	23 (150)	4 (11)	6 (44)	11 (66)	63
Gynecology/obstetrics	337/180	16 (56)	3 (10)	4 (16)	5 (20)	
Cardiovascular surgery	175	201 (615)	66 (178)	66 (178)	84 (219)	144
Internal medicine	65					29
Gastroenterology	325	23 (107)	4 (10)	6 (32)	16 (56)	
Nephrology	221	29 (150)	4 (12)	8 (41)	21 (70)	
Oncology	416	15 (104)	3 (10)	4 (27)	15 (50)	
Cardiology	527	10 (78)	5 (9)	4 (20)	12 (40)	

Table 1: Blood loss during hospital stay caused by laboratory tests in eight different clinical disciplines. The numbers give medians with the 95 percentiles in brackets (according to 280)

When using the tube sizes recommended the lab subspecies used up the following percentages of total blood loss (median): haematology 26 %, coagulation: 17 %, clinical chemistry 45 %, other tests 11 %. The authors reported that only 5 % of patients had a blood loss of > 196 mL, much less than reported in literature. They recommend giving a weekly report to the users of the laboratory on the volumes sent from each patient (280).

4. Analyte Stability in Sample Matrix

The aim of a quantitative laboratory investigation is to determine the concentration or activity of a diagnostically relevant analyte in a body fluid in order to provide information on the clinical situation of a patient. This implies that the composition of the samples for analysis must not change during the preanalytical phase (sampling, transportation, storage, sample preparation).

4.1 Stability and Instability

Stability is the capability of a sample material to retain the initial property of a measured constituent for a period of time within specified limits when the sample is stored under defined conditions (119).

The measure of the instability is described as an absolute difference, as a quotient or as a percentage deviation of results obtained from measurement at time 0 and after a given period of time.

Example:

The transportation of whole blood for 3 to 4 hours at room temperature increases the concentration of potassium from 4.2 mmol/L to 4.6 mmol/L.

Absolute difference:	0,4 mmol/L
Quotient:	= 1,095
Percent deviation:	+ 9,5%

The maximum permissible instability is the deviation of a result that corresponds to the maximum permissible relative imprecision of the measurement. This was defined as 1/12th of the biological reference interval (204). The deviation should be smaller than half of the total error derived from the sum of biological and technical variability (74, 205). The stability of a blood sample during the preanalytical phase is defined by the temperature, the mechanical load in addition to other factors. As time has also a major influence, the stability is stated as the maximum permissible storage time under defined conditions.

The maximum permissible storage time is the period of time at which the stability requirement of 95 % of the samples is met. This is a minimum requirement, since under pathological conditions the stability of a constituent in the sample can be considerably reduced (see examples in 6. Table).

The storage time is stated in suitable units of time (days, hours, minutes). A clear distinction must be made between the storage of the primary sample (blood, urine, cerebrospinal fluid) and the storage of the analytical sample (e.g. plasma,

serum, sediment, blood smear). The storage times are adopted for:

1. Storage of the primary sample at room temperature (20 to 25 °C).
2. Storage of the analytical sample at room temperature (20 to 25 °C), refrigerator temperature (4 to 8 °C) and deep-frozen (-20 °C).

4.2 Quality assurance of the time delay during the preanalytical phase

Transport time

The transport time is the difference between the blood sampling time (in general with an accuracy of at least a quarter of an hour) and the registration time of the request and/or the arrival of the sample at the laboratory. The transportation time for each sample should be documented by the laboratory.

Preanalytical time in the laboratory

The preanalytical time in the laboratory is the difference between the time of analysis and the registration time of the sample. When the time at the end of the analytical phase (i.e. printing time of the result) is noted, the analysis time stated in the description of the method must be subtracted.

Documentation

It is recommended to state the sampling time and the arrival time of the sample in the laboratory in the report for the documentation of the transport time.

Actions to be taken when the maximum permissible preanalytical times are exceeded

A medically relevant change to the results must be considered when the maximum permissible transport and preanalytical time of the sample has been exceeded. The laboratory has the responsibility to mark the results of such samples with a note in the report, or to refuse to carry out the test. The latter decision is advisable when medical conclusions may be derived from the result that may be detrimental to the patient. The following example illustrates the problem:

An EDTA blood sample shows a rise in monocyte number from 4 to 10 % after four hours of storage, measured by an automatic cell counter system. When this result is reported without comment, it could lead to an erroneous medical diagnosis that the patient suffers from a viral infection. Therefore, the clinician should be informed with a comment or a refusal, such as:

Comment: "The monocyte count may give incorrectly high values with the method used in our laboratory when EDTA blood is stored more than 2 hours. A control in the smear resulted in normal monocyte counts."

Refusal: "The maximum permissible transportation time was exceeded. Therefore the monocyte results are not stated, because they cannot correctly be determined. For the determination of correct monocyte counts, a maximum transportation time of two hours is acceptable."

5. The Haemolytic, Icteric and Lipaemic Sample

Medical laboratory tests are affected by endogenous and exogenous factors in the sample matrix. Certain potentially interfering factors may be recognised by a coloured appearance of the sample, whereas other factors (e.g. drugs) are detected only by additional information and/or direct analysis. Reference books provide useful information on drug interferences in laboratory analysis (262, 288). Publications of standard setting organisations describe the methodology and statistical methods for the recognition and quantitative estimation of interferences in clinical chemical investigations (39, 85, 86, 239).

It is difficult to predict the effects of haemolysis, turbidity (lipaemia) and bilirubin (icterus), especially when reagents and analytical systems undergo modification (39, 74, 239). This document provides information that the laboratory can consider as appropriate actions to ensure that the results of measurement are clinically relevant.

5.1 Definition of a clinically relevant interference

The maximal allowable deviation (bias) is expressed in % deviation of the result without interference as determined by a reference method. A clinically relevant bias should be considered if the change of the result caused by the interfering substance is more than the maximal allowable deviation of the analytical procedure (204). The bias usually amounts to 1/12 (which is about 8%) of the reference interval.

Data on the biological variability was published to define the medical needs (205). The desirable bias (B) derived from intra-individual (CV_w) and inter-individual (CV_b) variation was established for 316 analytes (205).

Example:

A result for plasma creatinine of 90 $\mu\text{mol/L}$ (1.02 mg/dL) was measured in an icteric sample by a routine method, whereas a creatinine concentration of 125 $\mu\text{mol/L}$ (1.41 mg/dL) was measured in the same sample by a reference

method. For creatinine, the maximum allowable deviation amounts to 11.5 % (204). The result deviates by 35 $\mu\text{mol/L}$, which is 28 % from the expected value. Both criteria confirm that hyperbilirubinaemia is a clinically relevant interference when creatinine is measured using the routine method established in the laboratory.

5.2 General recommendations

Documentation of interferences

Documentation of method: Each clinical laboratory should specify the constituents in the quality manual that are affected by any of the following properties of the sample. The limits, beyond which the analysis shall not be performed, should be stated for each method that is subject to an interference. The European Directive for In Vitro-Diagnostics (IVD) states that providers of reagents must define the appropriate limiting conditions (62). The procedure for the detection of interfering properties as well as actions that should be taken with the sample, should be documented in the quality manual.

Detection of a potentially interfering property and handling of sample and request

Each sample must be visually examined immediately after arrival, or after centrifugation (in the case of blood samples) and the potentially interfering property recorded in the laboratory journal and report. When no visible interference is observed, it should be registered in the list by the notation: "appearance unremarkable".

The requests should be reviewed to identify analytes that could be affected by the observed interference in the sample. Analytes that are not affected by the interference in the sample are measured as in samples that contain no interference using the routine method of analysis. A sample that may be expectedly affected by an identified interference must be pre-treated to eliminate the interference before measurement is made; alternatively a measurement method may be used that is not subject to the interference. The analysis should not be made when a clinically relevant bias is expected, or if the interference cannot be eliminated or circumvented by an appropriate alternative method.

Reporting results

Each report should include a notation characterising the sample's "appearance". The observation should be documented for each sample: e.g. "haemolytic", "icteric", "opalescent", "turbid", or "lipaemic", if a relevant colour or turbidity was identified.

The report should indicate that the analysis was made despite a remarkable appearance of an interferent in the sample. The report should also indicate when the sample was pretreated prior to the analysis. If the interference in a sample cannot be eliminated for a subsequent analysis, the text "impaired by..." should replace the report of the result.

5.3 The haemolytic sample and the effect of therapeutic haemoglobin derivatives

Definition and mechanisms of haemolysis

Haemolysis is defined as the release of intracellular components of erythrocytes and other blood cells into the extracellular space of blood (92). Haemolysis can occur *in vivo* (e.g. through a transfusion reaction or during malaria parasite infection affecting the invaded erythrocytes), and *in vitro* during all steps of the preanalytical phase (sampling, sample transport and storage).

Haemolysis is caused by biochemical, immunological, physical and chemical mechanisms (23, 92). During blood transfusion, complement-dependent haemolysis may be caused by antibodies reacting with the major blood group antigens. Physical haemolysis is caused by destruction of erythrocytes by hypotonicity (e.g. dilution of blood with hypotonic solution), as well as decreased (vacuum) or increased pressure. Mechanical haemolysis may occur during the flow of blood through medical devices (e.g. catheters, heart valves) *in vivo*, during inadequate centrifugation as well as at elevated temperature *in vitro*. Contaminating substances may also cause *in vitro* haemolysis. Finally, detergents (residual cleaning agents and disinfectants) and other contaminating substances may cause haemolysis.

After the separation of blood cells, haemolysis may be visible by the red colour of serum or plasma. The sample may concomitantly be contaminated by constituents of other blood cells (leukocytes and platelets). For example, cell breakdown may result in changes in blood of patients with leukaemia; the disintegration of platelets during coagulation results in higher concentrations of intracellular platelet constituents in serum (163). On the other hand, the intracellular components of erythrocytes are also released into plasma without a concomitant increase in haemoglobin concentration during storage of whole blood in refrigerators.

Haemoglobin based oxygen carriers used as blood substitutes

Therapeutic haemoglobin derivatives (so-called HbOC = haemoglobin-based oxygen carriers) were recently developed as blood substitutes. The substitutes occur at concentrations of up to 50 g/L in plasma of patients under blood substitute treatment. Plasma or serum containing blood substitutes has a strong red colour (32, 125, 283).

Detection and measurement of haemoglobin in serum or plasma

Visual detection

At extracellular haemoglobin concentrations above 300 mg/L (18.8 $\mu\text{mol/L}$), haemolysis is detectable by the red colour of serum or plasma. Samples with therapeutic haemoglobin derivatives (in therapeutically effective concentration) are always intensely red coloured.

Spectrophotometric detection

Some analytical systems measure the extent of haemolysis by comparing the absorption of samples at two wavelengths (88). The absorption spectrum of the haemoglobin derived oxygen carriers used as blood substitutes does not differ substantially from that of natural haemoglobin.

Analytical measurement

Haemoglobin in plasma or serum is measured at concentrations that are below the concentration visible to the human eye (16, 144, 255).

Distinction between *in vivo* haemolysis and *in vitro* haemolysis

In vivo haemolysis may be distinguished from *in vitro* haemolysis by comparing a haemolytic sample of a patient with other samples from the same patient, arriving at the same time.

In vivo haemolysis

Free haemoglobin *in vivo* rapidly binds to haptoglobin and the complex is eliminated from the circulating blood (as in haemolytic anaemia). Consequently, haptoglobin is reduced during intra-vascular haemolytic processes. The measurement of low concentration of haptoglobin thus permits an imperative assessment of haemolysis (exceptions are inborn haptoglobin deficiency and newborn children (268)). Likewise, the measurement of haemopexin and/or methaemoglobin/albumin was used to characterize *in vivo* haemolysis (268).

A rise in concentration of indirect bilirubin and reticulocyte counts is a typical sign of *in vivo* haemolysis, which in turn leads to increased erythropoiesis. Other consequences of *in vivo* haemolysis, such as a change in the LDH isoenzyme pattern, seem less suitable for the identification of haemolysis because of their low diagnostic sensitivity and specificity.

In vitro haemolysis

After *in vitro* haemolysis all constituents of erythrocytes, including potassium concentration, lactate dehydrogenase and aspartate aminotransferase activities, increase in addition to the concentration of free haemoglobin in plasma or serum (279). In contrast, haptoglobin concentration in plasma/serum of haemolytic samples remains unchanged. Certain immunological methods differ in their ability to distinguish haemoglobin/haptoglobin complexes from free haptoglobin (268).

Identification of haemoglobin derived oxygen carriers

Therapeutic haemoglobin derivatives yield a visible haemoglobin concentration within the range of 10 - 50 g/L. The absorption spectrum of haemoglobin derived oxygen carriers is not distinguishable from that of haemoglobin (32, 125, 283). However, haemoglobin concentrations of this magnitude rarely occur in vivo; therefore the use of therapeutic haemoglobin derivatives must be suspected at this plasma haemoglobin concentration. Haptoglobin cannot be used for discrimination, since the oxygen carriers only form complexes slowly with haptoglobin.

Mechanisms of interference by haemolysis

Haemolysis in vivo or in vitro can cause an apparent decrease or increase of results. A variety of mechanisms are contributing to these effects, some of which are summarized below:

Rise of intracellular constituents in the extracellular space

Cell constituents with an intracellular concentration 10 times higher than the extra-cellular concentration, will increase in plasma/serum during haemolysis (e.g. potassium, lactate dehydrogenase, aspartate aminotransferase). Differences of analyte concentrations between plasma and serum are also due to lysis of blood cells (essentially by platelets): thus, neuron specific enolase, potassium and acid phosphatase are higher in serum.

Interference with analytical procedure

Blood cell constituents can directly or indirectly interfere in the measurement of analytes. Adenylate kinase released from erythrocytes causes an increase of creatine kinase and CK-MB activity especially when inhibitors of adenylate kinase in the assay mixture are inadequate (248). In contrast, adenylate kinase does not affect the immunochemical quantification of CK-MB. Pseudo-peroxidase activity of free haemoglobin interferes in the bilirubin procedure of Jendrasik and Groof by inhibiting the diazonium colour formation (267). Proteases released from blood cells reduce the activity of coagulation factors while fibrin split product formation may increase.

Optical interference by haemoglobin

The effect of haemolysis on various analytes measured in clinical chemistry has been thoroughly investigated (25, 88, 238). Most often, the colour of haemoglobin increases the absorption at a respective wavelength or changes the blank value. An apparent increase or decrease of a result by haemoglobin is therefore method- and analyte concentration-dependent. Likewise, the changes caused by therapeutic haemoglobin derivatives are primarily due to optical interference (32, 125, 283).

Means to avoid haemolysis and its interferences

Haemolysis in vitro can almost always be avoided, when the mechanism of haemolysis is known. Therefore each haemolytic sample should be documented and the cause of haemolysis identified.

The most frequent causes of haemolysis, such as errors during sampling, are avoided using standardised materials and methods for the preanalytical processes and by training and individual counselling.

Occasionally reliable results can only be obtained from a truly non-haemolytic sample. In some cases, the interference can be reduced or excluded using a method that is not sensitive to haemolysis or by pre-treatment of the sample. Procedures including deproteinisation or molecular sieving (71, 73) and others, have been found to be not useful, because of the work load involved. Today, a modification of the methodology, e.g. by using a blanking procedure by means of measurement at a second, appropriate wavelength, is preferred, although, this procedure may not be applicable for the analysis of blood from patients who received blood substitutes (85). Likewise the ultrafiltration procedure, as applied in the multi-layer film technology, reduces the effect of interference by haemolysis (240).

Reaction upon the receipt of haemolytic samples

Each laboratory should document the procedures that are affected by haemolysis and to what extent they are affected. The procedures on how to handle haemolytic samples should be described in the quality manual. This includes the criteria for rejecting the execution of analysis.

The haemolysis of each sample must be documented and reported to the clinician who ordered the analysis.

When haemolysis occurs in all samples of a patient, haemolysis in vivo may be suspected. This must be immediately reported to the clinician to verify the possible causes of haemolysis or the possible use of synthetic haemoglobin derivatives.

After estimation of the degree of haemolysis the sample is treated for analysis according to the degree of interference. The results of measurement may be reported as follows:

- Method not impaired: report results as with non-haemolysed samples.
- Method impaired, but eliminated by pre-treatment: report results after pre-treatment.
- Method impaired in a clinically relevant way: instead of providing a result, report: "Impaired by haemolysis".

It is not recommended to correct a measured result for haemolysis arithmetically using the haemoglobin concentration as an indicator.

5.4 The lipaemic sample

Definition

Lipaemia is a turbidity of serum or plasma which is caused by elevated lipoprotein concentrations and which is visible by the eye. A sufficiently transparent sample container is a prerequisite to detect lipaemia. Visible detection of lipaemia is also dependent on the type of plasma lipoproteins at elevated concentrations in the sample. Post-centrifugal coagulation of serum samples of heparinized patients can also be the cause of turbidity.

Causes of lipaemia (turbidity)

Most often, lipaemia results from increased triglyceride concentration in plasma/serum. This can be due to food intake, altered lipid metabolism or infusion of lipids. After intestinal absorption, triglycerides are present in plasma as chylomicrons and their metabolites (remnants) for six to twelve hours.

One to four hours after intake of a "Continental" or "American" breakfast, plasma triglyceride concentrations increase substantially. As they cause turbidity of the sample, the patient should be requested to fast before investigations are made that are affected by lipaemia.

The following causes of plasma turbidity should also be distinguished: Metabolic disorders causing hypertriglyceridemia, lipid infusions, cold agglutinins and monoclonal immunoglobulins.

Identification and quantification of lipaemia

Visual and photometric methods for serum and plasma samples

In whole blood triglyceride concentrations above 1000 mg/dL (11.3 mmol/L) cause turbidity that is detected by visual inspection. Lipaemia in plasma or serum is visually observed at triglyceride concentrations above 300 mg/dL (> 3.4 mmol/L). The extent of turbidity of serum/plasma samples is measured at wavelengths above 600 nm (e.g. 660/700 nm) (240).

Detection in EDTA blood

Haematological tests are influenced by lipaemia. Thus, haemoglobin concentration is apparently increased by light scattering. The turbidity is detected by spectrophotometric analysis. The result of a centrifuged sample from the same patient taken at the same time can be used for comparison.

Mechanisms of the interference by lipaemia on analytical methods

Interferences in spectrophotometric analysis

Lipaemia interferes in photometric measurement by light scattering and light absorption. The apparent result can be either increased or reduced depending on the blanking procedure. At high turbidity, no measurement may be possible due to the limits of the linearity of the method (9).

Volume depletion effect

Lipoproteins decrease the apparent concentration of the analyte by reducing the available water of sample volume, since the volume occupied by lipoproteins in plasma or serum is included in the calculation of the analyte concentration. This explains why lower sodium and potassium concentrations are found in lipaemic sera, when plasma or serum is measured by flame photometry and by indirect measurement using ion-sensitive electrodes, in contrast to direct potentiometry (141). The same observation is made after centrifugation, when the lipoproteins are not homogeneously distributed in serum/plasma samples: the concentration of an analyte dissolved in the aqueous phase is less in the upper layer than in the lower phase of the sample. The converse is true for concentration of lipids and lipid soluble constituents, including certain drugs that are taken up by lipoproteins.

Interference by physico-chemical mechanisms

A constituent that is extracted by lipoproteins may not be accessible for the reagent, such as an antibody, for detection. Similarly, electrophoretic and chromatographic procedures may be affected by lipoproteins present in the matrix.

Means to avoid lipaemia and interferences caused by turbidity

To avoid interference of lipoproteins on measurement after oral intake of fat, the patient should fast at least twelve hours before blood samples are taken (100, 253). In patients receiving parenteral infusion of lipids a period of eight hours of interruption of the treatment is necessary to avoid interfering turbidity (99). If these measures do not provide a non-turbid sample, other causes of turbidity should be suspected.

Several methods were recommended to remove lipids from serum or plasma, such as centrifugation, to produce a clear infranatant sample. Other methods include the extraction of lipids with organic solvents or fluorine chlorinated hydrocarbons (e.g. Frigen®) and the precipitation of triglyceride rich lipoproteins by polyanion and cyclodextrin (227).

Centrifugation

Centrifugation at 1000 g is effective, when chylomicrons cause turbidity. In contrast, at least 10 min centrifugation at 12 000 g separates serum or plasma lipids by flotation.

The clear infranatant must be carefully separated for analysis. Ultra-centrifugation must be employed for the separation of low density lipoproteins and high-density lipoproteins. A centrifugation time of at least 30 min at a speed above 40 000 g is recommended. The separation of lipaemic plasma from EDTA-blood in samples used in haematology can be performed by centrifugation and exchange of the cell-free supernatant with the same volume of isotonic NaCl solution.

Polyethylene glycol

The plasma/serum sample is mixed 1 + 1 (v/v) with 8 % polyethylene glycol 6000, incubated for 30 min in a refrigerator at 4 °C and centrifuged afterwards for 10 min at 4 °C and approx. 1000 g. The results determined in the clear supernatant are multiplied by the dilution factor 2 (199, 215).

α-Cyclodextrin

200 g α-cyclodextrin is dissolved in 1 L distilled water and kept in a refrigerator. Before use, α-cyclodextrin solution must be brought to ambient temperature. Thoroughly mix one part of α-cyclodextrin solution with two parts of serum, and centrifuge for 1 min at 10 000 g. The clear supernatant can be used for analysis. The dilution must be considered when calculating the concentration of the constituent in the original serum sample.

Experiments revealed that the results on 20 serum constituents are not affected by the precipitation of lipoproteins using α-cyclodextrin (227).

Other methods for delipidation

Four different procedures for the extraction of lipids from serum samples were examined (3), including Freon 113^o, dextrane sulfate 500 S, Aerosil 300 and a butanol/diisopropylether mixture. It was found that the delipidation methods may substantially alter the concentrations of certain analytes. Even the use of magnetic beads is not generally applicable (97).

Optical clearing systems

Commercial test kits may contain detergents such as triton X-100, cholic and desoxycholic acid, lipase or cholesterol esterase to remove turbidity in plasma or serum samples. The assigned concentrations of these substances are method dependent and should not be changed by the user.

Recommendation

A visible turbidity of a sample must be documented and reported with the results. Transparent sample containers must be used to detect turbidity. The methods used for the measurement of certain analytes that are affected by lipaemia must be listed; the methods for delipidation and the criteria for their application must be documented in the quality manual.

The method of choice for removal of turbidity from serum and plasma is a 10 min centrifugation in a micro-centrifuge with 10 000 g.

When chemicals are added (e.g. polyethylene glycol, α-cyclodextrin), the laboratory must prove that the assigned method for measurement is not disturbed by the agent.

Samples submitted for the determination of lipids and other analytes may be delipidated only after measurement of the lipids. This also applies to lipid-soluble drugs.

Test of interference by lipaemia

Various problems should be considered when examining the influence of lipaemia on analytical methods. Unfortunately, there is no uniform human lipid standard available. Patient samples with high lipid concentrations should not be frozen.

A 10 or 20 % emulsion of vegetable fat as applied in parenteral nutrition (5, 28, 41, 88, 147, 177, 209) is suitable to simulate lipaemia. Significant differences between the effects of the "physiological" and the artificially produced lipaemia were observed, particularly in measurements of urea and potassium (41). Therefore because the observations may not be transferable to the biological condition the effect of lipaemia may not be examined using exclusively a model that contains artificial fat emulsions.

5.5 The icteric sample

Appearance of different bilirubin species

Bilirubin occurs in plasma as a free molecule and covalently bound to albumin. In addition, water-soluble bilirubin conjugates exist as mono- and diglucuronides (12). Studies on bilirubin interference were based mainly on experiments in which free bilirubin or water-soluble di-taurobilirubin was added to serum (39). Under certain conditions the bilirubin molecules differ qualitatively and quantitatively in their effects of interference (88).

Conjugated bilirubin appears in urine, when present at increased concentrations in blood. In patients with proteinuria, bilirubin bound to albumin can also appear in urine.

After intra-cerebral bleedings non-conjugated (free) bilirubin causes xanthochromia of the cerebrospinal fluid. At increased permeability of the blood-brain barrier bilirubin bound to albumin can appear in the CSF.

Mechanisms of bilirubin interference

Spectral interference

Bilirubin has a high absorbance between 340 nm and 500 nm wavelengths. Therefore, the range of the linearity of a spectrophotometric procedure, using these wavelengths for the measurement of an analyte, can be a limiting factor because of the high background absorbance caused by bilirubin (70, 209). In coagulation analysers using turbidimetric principle, a bilirubin concentration exceeding 25 µmol/L causes clinically relevant changes of the measured values of antithrombin III. Interference of bilirubin at higher concentrations will also be significant in certain coagulation tests (210).

The reduction of absorption as a result of oxidation of bilirubin in alkaline solution is the main cause for bilirubin interference in modifications of the Jaffé method without deproteinisation (70).

In a strongly acid solution the absorption of conjugated bilirubin shifts to the UV wavelengths. Therefore bilirubin interferes in the determination of phosphate using the phosphomolybdate method through its reducing effect (55, 88).

Chemical interference

Bilirubin interferes in oxidase/peroxidase based test systems. Proportionally to its concentration bilirubin reacts with H₂O₂ formed in the test system which causes systematically lower results in enzymatic procedures that are used for the measurement of glucose, cholesterol, triglycerides, urate and creatinine (88, 241). Bilirubin competitively interferes with dyes binding to albumin (153). However, di-taurobilirubin does not interfere in the procedure of dye binding to albumin (88).

Detection and documentation of increased bilirubin concentrations in clinical samples

The visual inspection of plasma or serum samples for the detection of hyperbilirubinaemia is often not sensitive enough. This is particularly true when samples are simultaneously stained by other pigments (e.g. haemoglobin and its derivatives). Moreover, adhesive labels on primary containers can impair visual inspection.

Hyperbilirubinaemia is directly detected in diluted samples that are measured at 450 and 575 nm (240). (The direct procedure of bilirubin measurement is only applied for the determination of hyperbilirubinaemia in newborns.) With the nutritional supply of carotenes or carotinoids, bilirubin concentration by direct measurement is overestimated (77). The common clinical chemical methods are applied to quantitatively measure the interference caused by bilirubin. It is advisable to separate and measure the different bilirubin fractions to assess the mechanism of interference (12).

Prevention of bilirubin interference

Method selection

The high prevalence of hyperbilirubinaemia in patients from intensive care, gastroenterological, surgical or paediatric departments makes it pertinent to select analytical methods that are less susceptible towards bilirubin interference.

Blanking procedures are useful to eliminate spectral bilirubin interferences, (283). Parallel sample blank values give better results than methods in which reagents are added successively into a cuvette (88). Blanking procedures are often part of the analytical procedure, e.g. in the kinetic method for creatinine determination according to the Jaffé principle, when autoanalysers are used (220).

The chemical interference of bilirubin in an analytical reaction is not eliminated by blanking procedures. K₄(Fe(CN)₆) effectively eliminates bilirubin interference in H₂O₂-forming enzymatic methods based on the Trinder reaction (8, 215). Moreover, optimal concentrations of components of the Trinder reaction can reduce the interference by bilirubin. A mixture of non-ionic tensides may reduce bilirubin interference such as in the spectrophotometric determination of inorganic phosphate using phosphomolybdate (85).

Actions recommended for use in procedures sensitive to bilirubin

When procedures susceptible to bilirubin interference are used, the laboratory must know the limit of bilirubin concentrations where interference-free measurements are possible (application limit). The limit depends on the maintenance status of the analytical system and other variables. Unfortunately, manufacturers' data is not always available. For the determination of the application limit, 2 mL

of 20 mg free bilirubin, dissolved in 0.1 mol/L NaOH, is mixed with 20 mg ditaurobilirubin, dissolved in 2 mL distilled water, in the dark. Five mL of non-icteric pool serum is added to 0.1 mL of the master solution to prepare a final bilirubin concentration of approximately 340 $\mu\text{mol/L}$ (20 mg/dL). Serial dilutions are prepared by mixing a non-icteric pool serum with the master solution at different proportions. The test solution must be used on the same day (39).

Suitable alternative procedures must be applied for samples that have bilirubin concentrations beyond the application limit. The procedures may require a pre-treatment of samples to remove bilirubin. For the determination of serum creatinine using a bilirubin-susceptible enzymatic method the sample is pre-incubated with 4.4 kU/L bilirubin oxidase for 30 seconds (8). However, the low stability of bilirubin oxidase limits the practical application of this procedure. Ultrafiltration of serum was also used for the elimination of bilirubin interference in creatinine assays (73). As bilirubin binds to proteins, serum is centrifuged in a centrifugable ultrafilter (cut off \approx 20 kD) for 15 min at 2000 *g* to remove bilirubin and obtain a completely protein-free ultrafiltrate. The volume depletion effect of proteins results in an approximately 4 % higher value for creatinine in the ultrafiltrate (73). The distribution of ionised low-molecular weight analytes on the diaphragm may be pH dependent which has an effect on the measurement results (71).

If procedures for the elimination of bilirubin are not applicable, alternative analytical principles should be applied. Immunological procedures for the measurement of serum albumin can be used to replace dye binding methods that are susceptible to bilirubin interference.

6. Table: Samples and Stability of Analytes

Key for tables

- ⊕ Recommended sample
- + Can be used without changes of result
- (+) Can be used with limitations (see comments, in case of citrated plasma this indicates the need to consider dilution by citrate (143)).
- Not recommended
- Decreased (↘) or increased (↗) results may be obtained in comparison to recommended samples.
- Blank field means: no data was found in literature.
- Greek letters refer to the information provided by diagnostic companies, numbers in brackets to the references.

Stability and half-life times
 min = minute(s) h = hour(s)
 d = day(s) w = week(s)
 m = month(s) y = years(s)

Information provided by Diagnostic Companies

- α: Ortho-Clinical Diagnostics; Vitros Systems
- β: Abbott; AxSYM, Architect,
- γ: Roche Diagnostics; Roche/Hitachi, Elecsys®, Modular
- γγ: Roche Diagnostics; Cobas INTEGRA®
- δ: Beckmann-Coulter; Synchron LX/CX, Immage/Array, Access
- ε: Siemens Healthcare Diagnostics; Dimension®, BN-Systems, Stratus CS
- Ω: Beckmann Coulter, Olympus-Analysers
- κ: Siemens Healthcare Diagnostics; Immulite
- λ: Bio-Rad
- μ: Siemens Healthcare Diagnostics; ADVIA Centaur/ACS 180
- α: Siemens Healthcare Diagnostics, Enzygnost

6.1 Blood

Analyte	Samples					Stability							References	
	Serum	Heparin Plasma	EDTA Plasma	Citrated Plasma	Whole blood Hep EDTA Citrat	Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/ Comments		
								-20°C	4-8°C	20-25°C				
Acetaminophen													see Paracetamol	
Acetylsalicylate	+	+β	+β	(+)β		15-30 min								65
α ₁ -Acid glycoprotein (orosomucoïd)	+	+γ,ε,Ω	+γ,ε,-γγ, Ω	(+)			11 d 4 w (2-8°C)	1 y	5 m	5 m				145, 258
Adenovirus antibodies	+		(+)										Complement fixation test, ELISA IgG, IgM	
Alanine aminotransferase (ALAT, ALT)	+	+	+	(+)		47 h	4 d↘	7 d	7 d	3 d↘				106, 140
Albumin colorimetric	+	+*	(+)↘+Ω	(+)		3 w	2-6 d 14 d (2-6°C)	4 m	5 m	2,5 m			*Bichromatic assay recommended for colorimetric assay(102).	27, 52, 76, 145, 222, 258, 271
nephelometric	+	+ε	+ε			3 w	6 d	3 m	1 w	4 h				
Aldosterone	+	+	⊕			min	1 d↘	4 d	4 d	4 d	EDTA			289
Alkaline phosphatase - total - bone isoenzyme	+↗ +	⊕ +	- -	(+) (+)↘		3-7 d 9-18 h	4 d↘ 4 d	2 m 1 m	7 d 7 d	7 d 7 d		EDTA binds essential cofactor zine.		100, 106, 271
Aluminium	-	-	-	-			7 d	1 y	2 w	1 w		Special tube needed		218
Amikacin	+	+	+β	(+)β		30 min-3 h		2 w	7 d	2 h				274, 290
Amiodarone	+	+	+			4 h-25 d	< 4 h	1 w	1 w	1 d		HPLC		100, 244
Amitriptyline	+	+	+			17-40 h				1 d		HPLC		275
Ammonia (NH ₄ ⁺)	-↗	(+)↗	⊕	-	+	min	15 min in EDTA↗	3 w	3 h	15 min	Serin 5 mmol/L + borate 2 mmol/L (72)	Do not use ammonium heparin. Contamination by sweat ammonia.		72
Amphetamines	+	+	+											275
Amylase - pancreatic - total	+ +	+ +	+ +	(+) (+)*		9-18 h 9-18 h	4 d↘ 4 d↘	1 y 1 y	1 m 1 m	7 d 7 d			*Possible decrease of the activity by Mg and Ca binding at > 25° C.	106, 161, 271, 289, 290
Amyloid A (SAA)	+	+ε						3 m ε	8 d ε	3 d ε				145

Samples										Stability					
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citrate Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	References
					Hep	EDTA	Citrat			-20 °C	4-8 °C	20-25 °C			
Androstendione	+								1 d Δ	1 y	4 d	1 d			132
Angiotensin converting enzyme (ACE)	+	+	-	-						1 y	7 d	1 d			164
Anticonvulsive drugs	+													See carbamazepine, ethosuccimide, phenobarbital, phenytoine, valproic acid	
Antimitochondrial antibodies (AMA)	+									1 m	7 d	1 d			43
Antineutrophil cytoplasmic antibodies (ANCA)	+									1 m	7 d	1 d			43
Antinuclear antibodies (ANA)	+									1 m	7 d	1 d			43
Antiphospholipid antibodies	+									1 m	2-3 d	1 d			43
Antistaphylococcal	+	+ γ	+ γ							6 m	2 d	2 d			
Antistreptodornase B	+									3 m	8 d				
Antistreptokinase	+														
Antistreptolysine	+	+ $\beta, \gamma, \delta, -\gamma\gamma$	+ $\beta, \gamma, \delta, -\gamma\gamma$							6 m	8 d	2 d			
Antithrombin - functional - immunochemical	- -	- -	- + δ, ϵ	\oplus (+) δ, ϵ			+*	40-135 h	8 h 2 d**	1 m 1 y	2 w 8 d	2 d		*Test by Pharmacia-Upjohn **after centrifugation	105, 137, 256, 259
α_1 -Antitrypsin	+	+	+ $\beta, -\gamma\gamma$	(+) β, γ					11 d 7 w (2-6 °C)	3 m	5 m	3 m		EDTA and citrate Δ	50, 145, 253, 254, 257, 289
APC resistance - functional screening test - genotyping factor V Leiden	- -	- -	- -	\oplus					30 min 1 w	6 m (-70 °C)	3 h	3 h		Centrifuge within 30 min	292
Apolipoproteins A1, AII, B	+ ∇	+	\oplus	(+)					36 h (4-8 °C)	3 m	8 d	1 d			44, 63 145, 189
Apolipoprotein CIII		+	\oplus	(+)	(+)					1 m	1 m	1 m			145, 189
Apolipoprotein E	+		+						1 d	3 m	8 d				216
ApoE-genotyping									1 w (4-8 °C)	3 m	1 w			Stability of ApoE ₂ >ApoE ₄ >ApoE ₃	216, 229
Aspartate aminotransferase (ASAT, AST)	+ ∇	\oplus	+ $\gamma, -\alpha, \Omega\Delta$	(+)				12-14 h	7 d Δ	3 m	7 d	4 d			106, 140, 253 289, 290
Aspergillus - antigen detection - antibody	+ +														
Atrial natriuretic peptide (ANP) - prohormone (pro ANP)			+* +					8,8 min 1 h	unstable 6 h	4 w	3 d	6 h	*Aprotinin	Centrifuge at 4 °C.	180, 184, 263

Samples										Stability					
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citratd Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	References
					Hep	EDTA	Citrat			-20°C	4-8°C	20-25°C			
Barbiturates	+	+						50-120h	2 d	6 m	6 m	6 m		See by phenobarbital	36, 65, 264
Bartonella spp. antibodies	+														
Batroxobin time	-	-	-	⊕						1 m	4 h	4 h		Avoid heparinate contamination ↗	105, 253, 289
Benzodiazepine	+	+						25-50 h	<1 d		5 m↘	5 m↘		See also diazepam, flunitrazepam, nitrazepam	65, 135, 155, 264
Bicarbonate	+	+	-		⊕			min	unstable↘ (30 min - 2 h at 4° C)	1 m	7 d	1 d*	Keep tube closed	*1 h after opening the tube, see also blood gases	29, 140, 289
Bilirubin - conjugated - total (also in newborns)	+	+	+	(+) (+)				h 17 d	unstable↘, ↗	6 m 6 m	7 d 7 d	2 d 1 d		Darkness required when stored >8 h.	27, 106, 271, 289
Biotin					⊕								deep frozen	uv-light sensitive	100
Blood cell surface markers (immunocytometry)					+	+			CD4 1 d in heparinised blood					See also lymphocyte subtypes	219
Blood gases (CO ₂ , O ₂ , pH)					⊕			min	<15 min↘ pO ₂ <30 min, pH, pCO ₂ <60 min on ice		2 h*		*In heparinised blood and closed tubes	Use closed gas tight tubes or capillaries	19, 29
Bordetella pertussis antibodies	+	+δ	+δ	+δ											
Borrelia burgdorferi antibodies (Lyme disease)	+	+σ	+σ	+σ										ELISA, Western blot	
Brain natriuretic peptide (BNP) - NT-pro BNP	+	+μ	⊕			⊕		13,4-20 min 2 h	4-5 h 1 d	5 d-8 m 1 y	1 d 5 d	4 h 3 d	EDTA		64, 124, 170, 175, 226, 233, 236
Brucella antibodies (Brucellosis)	+														
C ₁ -esterase-inhibitor, functional assay, immunochemical	+		+	(+) ε + ε						1 m 1 y	2 d 8 d	6 h		Stabilise plasma by freezing.	253
CA 125, (Cancer antigen 125)	+	+α, γ, μ	+α, γ, μ	(+)γ				5-6 d	2 d↘	3 m	5 d	3 d			22, 217, 246
CA 15-3, (Cancer antigen 15-3)	+	+α, γ, μ	+α, β, γ, μ	(+)γ				5-7 d	7 d	3 m	7 d	7 d			151, 217, 237, 246
CA19-9, (Carbohydrate antigen 19-9)	+	+	+γ, μ	(+)γ				4-9 d	7 d↘	3 m	30 d	7 d			217, 246
CA 72-4, (Cancer antigen 72-4)	+	+γ	+γ	(+)γ				3-7 d	3 d↘	3 m	30 d	7 d			217, 246
Cadmium	-		⊕	-				10-35 y	1 d in trace element tube					Special tube (Released from red stopper).	218, 289

Samples										Stability					References
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citrate Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	
					Hep	EDTA	Citrat			-20°C	4-8°C	20-25°C			
Calcitonin	+	+	⊕					min-h	4 h stabilised*	1 y	1 d	4 h	*Aprotinin 400 KIU/mL		100, 253
Calcium - total - ionised (free)	+	+	↓↓	↓↓	⊕			h min	2 d 15 min 1 d*	8 m	3 w 2 h	7 d 3 d	*Use calcium-titrated heparin (24)	pH-dependent **Stable in gel tubes for 25 h & 72 h after centrifugation in closed tube (123).	108, 271, 289, 24, 29, 123
Campylobacter jejuni/fetus antibodies	+														
Candida albicans - antibodies - antigen detection	+													Blood culture bottle	
Carbamazepine	+	+α	+β, γ	(+)α, β, γ, Ω				10-25 h	2 d	1 m	7 d	5 d		10% higher results in plasma (α), unstable in gel separator tubes, but stable in SSTII tubes (30)	30, 36, 65
Carbohydrate deficient transferrin (CDT)	+	+	+	(+)				5-10 d	3 d	3 m	2 w	1 d		Method-dependent	224
Carcino-embryonic antigen (CEA)	+	+	+α, β, γ, μ	+γ				2-4 d	7 d	6 m	7 d	2 d		EDTA reduces by 13% α	96, 179, 217, 237, 246, 269, 289
Cardiolipin antibody	+									1 m	2-3 d	1 d			43
Catecholamines (epinephrine, norepinephrine)	-	⊕	(+)	-				3-5 min	1 h if not stabilised	1 m 6 m stabilised	2 d	1 d	Glutathione 1.2 g/L + EGTA (26)	EGTA plasma to be separated within 15 min and frozen at -20°C.	26, 99
Ceruloplasmin	+	+	+,-γγ					4 d		1 y	2 w	8 d			254, 258, 271
Chlamydia antibodies (C. trachomatis, C. pneumoniae)	+		(+)								7 d	5 d		DNA-PCR possible after 3-4 d at room temperature.	173
Chloramphenicol	+	+β	+	(+)				2-5 h							274
Chloride	+	+	-	-	+			1 h	1 d	y	4 w	7 d			29, 106
Cholesterol	+	+	+,-α, γ, δ, Ω	(+)					2-7 d	3 m	7 d	7 d			11, 27, 44, 63, 106
Cholesterol, HDL	+	+	+β, λ, γ, δ, -α	-					2 d	3 m	7 d	2 d		3% lower cholesterol observed in EDTA plasma due to osmotic dilution effect	11, 44, 63
Cholesterol, LDL	+	+,-β, γ, Ω	+β, -γ, Ω	-					1 d	3 m	7 d	1 d			11, 44, 63
Cholinesterase, including dibucain number	+	+	+,-γ, Ω					10 d*	7 d	1 y	7 d	7 d		*Shorter in heavily diseased patients (76).	76, 106, 114, 246
Ciclosporin	-	-	-	-	⊕			10-27 h	13 d	3 m*	3 w*	3 w*	EDTA	*Stored in haemolysate	7, 66, 120, 274
Circulating immuno-complexes (CIC)	+								4 h	1 y	8 h	4 h			43
Clostridium tetani toxine antibodies	+														

Samples										Stability					References	
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citrate Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments		
					Hep	EDTA	Citrat			-20°C	4-8°C	20-25°C				
Coagulation factors																38, 105, 256, 292
Factor II	-	-	-	⊕				41-72 h	1 d	1 m		6 h			256, 292	
Factor V	-	-	-	⊕				12-15 h	4 h	1 m	2 d	6 h		Centrifuge at 4°C.	38, 105, 256, 292	
Factor VII	-	-	-	⊕				2-5 h	1 d	1 m	unstable	6 h			256, 292	
Factor VIII	-	-	-	⊕				8-12 h		2 w	4 h	3 h			38, 105, 256, 292	
Factor VIII R: Ag	-	-	-	⊕				6-12 h		6 m	7 d*	7 d*	*Sodium azide	Five freezing thawing cycles are possible.	261	
Factor VIII R: Co				⊕				6 h		6 m	2 w*	2 d	*Sodium azide		261	
Factor IX	-	-	-	⊕				18-30 h	1 d	1 m		6 h			256	
Factor IX: Ag	-	-	-	⊕					1 d						292	
Factor X	-	-	-	⊕				20-42 h	1 d	1 m		6 h			256, 292	
Factor XI	-	-	-	⊕				3-4 d	1 d		unstable	6 h			256, 292	
Factor XII	-	-	-	⊕				50-70 h	4 h		unstable	6 h			256	
Factor XIII	-	-	-	⊕				8-10 d		1 m		4 h			256, 292	
Cocaine Benzoylcegonin Ecgonine methyl ester	+	+	-						<10 min 5 d 10 d	4 d	30 d 5 d 10 d	<30 min 5 d 10 d	Fluoride, pH 5	Cocaine is converted in vitro into its metabolites	109, 155, 231	
Cold agglutinins														Keep whole blood at 37°C (water bath).		
Complement C3	+	+	+,-γγ	(+)				min	1 d, 2 d (C3 ₂) (2-6 °C)	8 d	8 d	4 d		Dependent on antibody, during storage C3 ₂ ↘, C3 ₂ ↘	145, 258, 271, 289	
Complement C4	+	+	+	(+)				12 h-1 d	1 d 2 d (2-6 °C)	3 m	8 d	2 d		During storage C4 ₂ ↘, C4 ₂ ↘	145, 271, 289	
Copper	+	+	-	-					7 d	γ	2 w	2 w		Special tube to avoid contamination.	271, 289	
Corticotropin (ACTH)		+	⊕					min	1-4 h↘	6 w	3 h 1 d*	1 h 2 d*	Aprolinin 400-2000 KIU/mL Mercaptoethanol 2 μL/mL	Prevent binding to glass tubes by using plastic for storage. *EDTA plasma	64, 178, 201, 253	
Corticotropin releasing hormone	+↘	+	⊕								2 d	11-18 h			64	
Cortisol	+	+α,μ	+α,γ,μ					1 h	7 d	3 m	7 d	7 d		11% less in EDTA (α)	50, 126, 289	
Corynebacterium diphtheriae toxine antibodies	+															
Coxiella burnetii antibodies (Q-Fever)	+															
Coxsackie virus antibodies	+															

Samples										Stability					
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citratd Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	References
					Hep	EDTA	Citrat			-20 °C	4-8 °C	20-25 °C			
C peptide	+	+	⊕					30 min	6 h	2 m	5 d	5 h	EDTA	Fluoride, oxalate also possible (β).	64, 79, 178
C-reactive protein (CRP)	+	(+)* +α, γ, γγ, δ, ε, Ω	+α, γ, γγ, δ, ε, Ω	(+), +γ				2-4 h	3 w (2-6 °C)	3 y	2 m	11 d		*patient-dependent lower results	145, 258, 289
Creatinine	+	+	+	(+)				3 min	2 d↘	3 m	7 d	7 d			27, 106, 271, 289
Creatine kinase (CK)	+	+	+β, γ, δ, -Ω	(+)				18 h	7 d↘	1 m	1 m	4 h	Darkness	CK-BB not stable	106, 253, 271, 289
Creatine kinase MB - enzyme activity - molecular mass	+	+,-α	+γ, δ, -Ω	(+)δ				12 h	7 d↘	1 y	7 d	2 d	SH reagent		165
	+	+β, γ, δ, -μ	+β, γ, δ, -μ	(+)γ				12 h	7 d↘	4 w	7 d	2 d			
C-terminal crosslinks-CTX (β-Cross-Labs™)	+	+	⊕						8 h 7 d (Crosslabs)	3 m	7 d	8 h 2 d*	pH 8.0, *EDTA	Stability pH-dependent.	157, 185
Cyclosporin														see ciclosporin	
Cyclic citrullinated peptide antibodies (CCP-antibodies)	+									1 y	7 d	1 d			43
Cytokeratine fragment 21-1 (CYFRA 21-1)	+	+γ	+γ	(+)γ				2-5 h	7 d	6 m	1 m	7 d			217, 246
Cystatin C	+	+	+					min		3 m	1 w	2 d		More stable in EDTA.	68, 145, 176
Cytokines - IFN-α, IFN-γ, -1α - IL-6 - IL-1β, sIL-2R, sIL-6R		+	⊕						2 h (heparinised blood) 1 h (EDTA)					see also Tumor necrosis factor (TNF)	14, 48, 54, 59, 69, 145
	-↘	+↗	⊕												
	-↘	+	⊕												
Cytomegalovirus - antigen detection (pp65) - DNA amplification - CMV antibodies															
	+	+β, σ	+β, σ	(+)β, σ											
D-Dimer	(+)	+	-	⊕				6-8 h	8-24 h 1 w	6 m	4 d	8 h			20, 31, 256, 292
Dehydroepiandrosteron sulfate (DHEA-S)	+	+β, γ	+β	(+)β				7-9 h	2 d↘	y	2 w	1 d			51, 132, 253
Dengue virus antibodies	+														
Diazepam	+	+	+					25-50 h			5 m	5 m			65, 155, 264
Differential leucocyte count - Band neutrophils - Segmented neutrophils - Eosinophiles - Basophiles - Monocytes - Lymphocytes	-	-	-	-					2 h-7 d*				Dry blood smear stable	K ₂ - or K ₂ -EDTA: Stability temperature- and instrument-dependent. *Prepare blood smear within 3 h after sampling. Do not store EDTA blood refrigerator.	103, 107, 213, 242
								6-7 h	2-12 h 3-12 h 12 h-6 d						
								1,5-3 y	2 h-2 d 2-12 h 3 h-7 d						
Digitoxin	+	+	+					6-8 d		6 m	3 m	2 w			65, 289
Digoxin	+	+	+	(+)β				1-2 d		6 m	3 m	2 w			65, 289
Disopyramide	+	+	+	(+)				4-9 h		5 m	2 w				65

Samples										Stability					
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citrate Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	References
					Hep	EDTA	Citrat			-20°C	4-8°C	20-25°C			
DNA analysis by polymerase chain reaction amplification (PCR)	(+)	-*, +	+		-*	⊕	+		1 w					* Heparin inhibits Taq polymerase and restriction enzymes, LiCl 1,8 mol/L eliminates this error (122, 181).	37, 112, 122, 181, 270
Dopamine		+	+					3-5 min		1 m	2 d	1 d			253
Echinococcus spp. antibodies	+														
ECHO virus antibodies	+														
Elastase							+							see pancreatic elastase	
Electrophoresis, protein - see also Lipoprotein electrophoresis	⊕	(+)								3 w	3-7 d	1 d		Fibrinogen to be considered when using heparinate plasma, may be eliminated by fibrin precipitation.	253, 257
Endomysium antibodies	⊕									m-y	7 d	1 d			43
Entamoeba histolytica antibodies	+														
Enterovirus antibodies	+														
Epslein barr virus - heterophilic antibodies (Paul Bunnel test) - anti-EBNA, -VCA, -EA	+		(+)											IgG, IgM, IgA; ELISA, Western Blot	
Erythrocyte count					(+)	⊕	(+)	2 m	4 d 7 d (4-8 °C)						89, 107
Erythrocyte sedimentation rate (ESR)							⊕		2 h					1 part citrate, 4 parts blood	253
Erythropoietin	+	+	+					4-11 h	6-24 h	5 m		2 w		Shipped frozen.	129, 253
Estradiol (E ₂)	+	(+)γ,μ, +α,β	(+)γ,μ, +α,β	(+)γ					1 d	1 y	3 d	1 d			51, 132, 289
Estriol (E ₃)	+	+								1 y	2 d	1 d			
Ethanol	+	⊕	+β,γ,γγ,δ	(+)β,δ			+*	2-6 h	2 w↗**	6 m	6 m	2 w	EDTA/Heparin	*10 g/L NaF recommended to stabilise. **Evaporation, use closed tubes.	83, 155, 171
Ethosuximide	+	+	+					30-60 h		5 m	4 w				65
Fatty acids	+	(+)↗*	(+)↘					2 min	30 min↗*	2 d	12 h	30 min		*Activation of lipase by heparin. Freeze serum/plasma immediately	271, 289
Ferritin	+	+,-Ω	+β,ε,(+)* γ,-γγ,Ω	(+)γγ					1 d	1-2 y	7 d	7 d		*Method-dependent	84, 252, 253, 289
α ₁ -Fetoprotein (AFP)	+	+	+	(+)				2-8 d	7 d	3 m	7 d	3 d			22, 128, 289
Fibrin(ogen) degradation products (FDP)	(+)*	-	-	(+)**					unstable↗↗	1 m	1 d	3 h	10 U thrombin and 150 KIU aprotinin/mL blood	*Special tube **Aprotinin or soybean trypsin inhibitor.	178, 254, 256
Fibrin monomers	-	-	-	⊕				<1 h	1 d	3 m	1 d	2 h			202, 256

Samples										Stability					References
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citrate Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	
					Hep	EDTA	Citrat			-20°C	4-8°C	20-25°C			
Fibrinogen - immunochemical - Clauss	-	+	-	⊕				4-5 d 4-5 d	1 w 1 w	1 m 1 m	7 d 1-7 d	7 d 1-7 d		Stability method-dependent	2, 15, 105, 183, 256, 259, 292
Fibrinopeptide A	-	-	-	⊕				3 min			2 h				256
Flunitrazepam	+								< 1 d*					*Store protected from light.	135
Folate - in erythrocytes	+	+γ,μ	+β,μ	(+)β	+μ	+β,δ		min	30 minΔ, 5 d (2-8 °C)	8 w	1 d	30 min	Ascorbate 2g/L	Haemolysate, prepared by 0.5 mL blood + 4.5 mL ascorbic acid (2 g/L). No-heparin interferes with AxSYM-Test (β).	142, 253, 289, 290,
Foliotropin (FSH)	+	+α,β,γ,μ	+α,β,γ,μ	(+)γ				min	7 dΔ	1 y	2 w	2 w			127, 289
Francisella tularensis-antibodies (tularemia)	+														
Free light chains (κ,λ) of immunoglobulins	+	+γ,δ,ε	+γ,δ,ε					2-6 h		6 m	1 m	7 d			50, 145, 234, 250, 251
Fructosamine	+	+	+					12 d	12 hΔ	2 m	2 w	3 d			249, 253
Galactose 1p-uridylyltransferase (galactosemia screening)						+*								*In newborns drop of blood on filter paper, analysed in erythrocytes	
Gastrin	+	⊕*	+	(+)					2 h			1 w*	*with aprotinin 2000 KIU/mL	Freeze serum as soon as possible.	64, 253, 289
Gastrin releasing peptide (GRP), pro GRP	+	+	+					2 min 1 d	1 h serum 3 h plasma	7 d	3-24 h	3-8 h*		*Plasma 8 h, serum 3 h.	246
Gentamicin	+	+β,γ,γγ,δ	+β,γ,δ	(+)β				0,5-3 h (<30 y of age) 1,5-15 h (>30 y of age)	4 h	4 w	4 w	4 h			65, 290
Glucagon	+	+	⊕						Unstable		1,5 d	30 h	Aprotinin 500-2000 KIU/mL	Stabilise	178
Glucose - venous - capillary	-ΔΔ -	-Δ -	-Δ, +** -	-Δ -	(+)	⊕		min min	10 minΔ, 2 h** 10 minΔ	1 d* 1 d*	7 d* 7 d*	2 d* 2 d*	Fluoride, mono-iodoacetate, mannose, acidity	*Stabilised haemolysate and plasma, **EDTA, citrate, fluoride tube (75).	57, 75, 81, 100, 253, 271, 289
Glutamat decarboxylase autoantibodies (GADA)	+		+											Add 25 mmol/L CaCl to EDTA plasma, centrifuge 10 min at 10000 g	182, 196
Glutamate dehydrogenase (GLDH)	+	+	+					18 h		4 w	7 d	7 d			253, 289
Glutamate oxalacetate-transaminase (GOT)														See aspartate aminotransferase	
Glutamate pyruvate transaminase (GPT)														See alanine aminotransferase	
γ-Glutamyltransferase (γ-GT)	+	+	(+)Δ,+α,Ω	(+)Δ,-γγ				3-4 d	1 dΔ	y	7 d	7 d			106, 140, 253, 289, 290

Samples										Stability					
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citrate Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	References
					Hep	EDTA	Citrat			-20 °C	4-8 °C	20-25 °C			
Glycated albumin														See fructosamine	
Gold	+														
Haematocrit					+	⊕			1 d 4 d (4-8 °C)		4 d*		*EDTA-blood	K ₂ - superior to K ₃ -EDTA	107
Haemoglobin A _{1c}						⊕	2 m		3 d (EDTA-blood)	6 m*	7 d*	3 d*		*Haemolysate	249
Haemoglobin F (HbF)						⊕	2 m								
Haemoglobin (whole blood)						⊕	2 m		4 d		7 d*	4 d *		*EDTA-blood	89, 107
Haemoglobin (plasma)	(+) ↗	⊕	⊕	(+)										Haemolysis during clotting (97).	16, 97, 144
Hantavirus antibodies RNA amplification	+				-	⊕	-								
Haptoglobin	+	+	+	(+)γ			3,5-4 d		8 d 7 w (2-6 °C)	3 m	8 m	3 m			254, 258, 271, 290
HbeAg	+	+β	+β	(+)β							7 d			also possible from ACD-B-, CRDA-1-, CPD- and Na-oxalate-tubes (β).	
HbsAg	+	+α,δ,σ	+α,δ,σ	(+)α,σ,Δδ			9 d			1 y	2 w	7 d			
Helicobacter pylori antibodies	+	+σ	+σ	(+)σ											
Heparin (anti Xa)				⊕										4 h	
Heparin associated thrombopenia; HEPA test	+						+		1 d		4 w			citrate blood and serum needed	
Hepatitis antibodies - anti-HAV - anti-HAV IgM - anti-HBs - anti-HBc - anti-HBe - anti-HCV - anti-Hepatitis D - anti-Hepatitis E	+	+β,δ,σ +α,σ +α,β,σ +α,β,δ,σ +β,σ +α,β,δ +β	+β,δ,σ +α,σ +β,σ +α,δ,σ +β,σ +α,β,δ +β	(+)β,δ,σ +α,σ +α,β,σ (+)α,β,δ,σ (+)β,σ +α,-β,δ (+)β			9 d			1 y 1 y 1 y 1 y 1 y 1 y	4 w 4 w 4 w 4 w 4 w 4 w	5 d 5 d 7 d 7 d 5 d 7 d		Prevent repeated freezing and thawing of sample.	100
Hepatitis B virus DNA	+		+								6 h				90
Hepatitis C virus - RNA amplification	+		+						6 h γ		3 d γ				111
Hepatitis D virus - RNA amplification	+		+												
Hepatitis E - RNA amplification	+		+												
Herpes simplex 1 or 2- virus antibodies	+	+σ	+σ	+σ											
HHV 6 antibodies (human herpes virus 6)	+														
HHV 6, 7, 8 - DNA amplification						⊕									

Samples										Stability					Remarks/ Comments	References
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citrate Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser			
					Hep	EDTA	Citrat			-20 °C	4-8 °C	20-25 °C				
HI virus-1 – (provirus) – DNA amplification – RNA amplification			⊕			⊕		5-14 d	7 d \searrow			7 d		Several freezing/thawing cycles possible.	111, 112, 113	
HI virus-1- and -2 antibodies	+	+ α, β, σ	+ β, δ, σ	(+) $\alpha, \beta, \delta, \sigma$								5 d γ	1-2 d		156	
HIV, virus load	\rightarrow	-	⊕	(+)	+	⊕	+	5-14 d	7 d			4 w	5 d		266	
HLA-ABC typing					⊕									Ammonium heparinised blood		
HLA-B27					+	⊕			1 d					Citrate phosphate-dextrose (CPD)		
HLA DR typing						⊕										
Homocysteine	+ \nearrow	+	⊕	(+)		⊕ λ			1 h \nearrow 6 h (2-6 °C)	4 y	4 w	4 d	Sodium fluoride 4g /L blood	Sample with EDTA/acidic citrate (0,5 mol/L). Store blood at -4 °C (277). Haemolysed EDTA sample in detergent stable for 2 d (194). Serum>Plasma.	6, 192, 194, 200, 208, 243, 277, 287	
HTLV I – antibodies (T-cell leukemia) – (provirus) – DNA amplification – RNA amplification	+		+			⊕									111	
Human choriongonadotropin (hCG) – total – free	+	+	+ β, γ	(+) α, γ				1-3 d 0,5-1,5 d	2 d 24 h (2-8 °C)	1 y 4 w	7 d 2 d	2 d			96, 127	
3-Hydroxybutyrate					⊕				4 h				2 d	Deproteinisation of whole blood	100	
IgA	+	+	+					6 d	8 d 1 m (2-6 °C)	8 m	8 m	8 m		EDTA and citrate \searrow	50, 145, 268, 271, 289	
IgD	⊕		\rightarrow					5 d				6 m	7 d	7 d		
IgE antigen specific IgE	⊕ +	+	+	(+) γ				2,5 d	7 d	6 m	7 d	7 d			145	
IgG IgG subclasses	+	+	+	-				3 w	11 d 1 m (2-6 °C)	8 m	8 m	4 m			50, 145, 268, 271, 289	
IgM	+	+	+ $\gamma, \delta, \epsilon, \Omega$ \rightarrow $\gamma\gamma$					5 d	17 d 1 m (2-6 °C)	6 m	4 m	2 m			145, 258, 271, 289	
Immunoglobulin (free) light chains (κ, λ)														See free light chains (κ, λ) of immunoglobulins		
Influenza virus ABC antibodies	+															
Insulin	\searrow (+)	+	+					5 min-6 h	15 min	6 m	6 d	1 d			64, 79, 151, 253, 289	

Analytes	Samples							Stability					References		
	Serum	Heparinate Plasma	EDTA Plasma	Citrate Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma				Stabiliser	Remarks/Comments
					Hep	EDTA	Citrat			-20°C	4-8°C	20-25°C			
Iron (Fe)	+	+	-	-				3 h	2 h	y	3 w	7 d			271, 279, 289
Islet cell antibodies (IA-2A)	+		(+)*											*See also glutamate decarboxylase autoantibodies (GADA)	182, 196
JC polyoma virus - antibodies (progressive multifocal leukoencephalopathy, PML) - DNA amplification (PML)	+						⊕								
Lactate	-	-	-	-	(+)			min	<5 min, unstable	1 m*	3 d 2 w*	8 h 6 d*	Mannose/fluoride, monoiodoacetate, deproteinisation	Use glycolysis inhibitor tube, if not immediately deproteinised. *Deproteinised in whole blood.	10, 253, 271, 289
Lactate dehydrogenase (LDH)	(+)	⊕	(+)	(+)				10-54 h LDH 5 < LDH 1,2	1 h	6 w	4 d	7 d		LDH in serum dependent on platelet number.	106, 167, 271, 289
Lead	-	-	-	-	(+)	⊕	(+)					7 d		special tube	218
Legionella antibodies	+														
Leishmania spp antibodies (visceral leishmaniasis)	+														
Leptin	+	+	+							2 y	2 m	3-6 d		Five freeze/thawing cycles possible.	64, 272
Leptospira spp antibodies (Leptospirosis)	+														
Leukocyte count					+	⊕	+	6-7 h	7 d		1 d*			See also differential count, *EDTA-blood	60, 89, 107, 159, 191
Lidocaine	+	+β, γ, γ	+β					1-3 h			6 h			Separator gel	133
Lipase	+	+α, Ω	+Ω, -	-				7-14 h		1 y	3 w	7 d		EDTA binds calcium (activator), 15% less activated in heparin(α).	253, 254, 271
Lipoprotein (a)	+	+γ, ε	+γ	-γ					1 d (4-8 °C)	3 m	2 w	2 d			158, 189, 190, 227, 230
Lipoprotein electrophoresis	⊕	+	+	-							2-5 d			Store at -20° C with 15% sucrose.	
Listeria monocytogenes - antibodies - DNA amplification	+						⊕								
Lithium	+	+*, α	-*, +α	-				8-24 h	1 h	6 m	7 d	1 d		*Do not use Li-heparin.	274
Lupus anticoagulant	-	-	-	⊕						6 m		4 h		Centrifuge platelet free.	43
Lutropin (LH)	+	+	+α, β, μ						7 d	1 y	5 d	3 d			51, 64, 127, 289
Lymphocytic choriomeningitis virus (LCM) - antibodies - RNA amplification	+						⊕								

Samples								Stability							
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citrate Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	References
					Hep	EDTA	Citrat			-20°C	4-8°C	20-25°C			
Lymphocyte subtypes					+	(+)			1 d (7 d*)					*Special stabiliser recommended (Cyto-Chex)	211
α_2 -Macroglobulin	+	+ γ, ϵ													50
Magnesium (Mg) – ionized	+ \nearrow –	+*** \oplus^*	–	– \searrow –	\oplus \oplus^*				1 d \nearrow 1 h	1 y 3 m	7 d 1 m	7 d 4 h	*Mg-balanced heparin (15-50 KIUL) (21)	**Separate blood cells before analysis (223), do not use siliconised tubes. ***higher obtained in Terumo gel-tubes	21, 57, 106, 223, 276, 289
Malaria – trypanosoma gambiense – plasmodium antibodies – plasmodium spp.	+					(+) \oplus								Microscopic examination of whole blood. Blood film of capillary blood.	
Measles virus – antibodies – RNA- amplification	+					\oplus									
Mercury (Hg)					+	\oplus								Special tube	275
Methadon	+	+													
Methotrexate	+						2-4 h			6 m	3 d			Light \searrow	65, 254
Mikrofilarias					+	+								Concentrated sample	
β_2 -Mikroglobulin	+	+ γ, ϵ, Ω	+ γ, ϵ, Ω	(+)			40 min		1 d	6 m	1 w	3 d			50, 145, 254
Morbili virus antibodies DNA amplification	+	+				\oplus									
Morphine total*	+	+							21 d 6 m (4 °C)	6 m	6 m	3 m		Light \searrow *after hydrolysis	232
Mumps virus antibodies	+	+ σ	+ σ	+ σ											
Mycobacterium spp. DNA amplification						\oplus									
Mycoplasma pneumoniae antibodies	+														
Myeloperoxidase (MPO)	+ \nearrow	+ \nearrow	+								7 d	8 h			228
Myoglobin	+	+	+	(+) γ			15 min		1 h \searrow	3 m	1 w	2 d			18, 49, 145, 165, 286
Neisseria gonorrhoeae antibodies	+														
Netilmycin	+						2-3 h								
Neuron specific enolase (NSE)	+ \nearrow	\oplus	+				1 d		2 h \nearrow	3 m 9 m (-80°C)	3 d	2 d	Heparin	Increased in Thrombocytosis Serum>plasma.	35, 91, 197, 253
Nitrazepam	+	+ β	+ β	(+) β					1 d*	1 w	1 w			*Light \searrow	155, 265
Opiates	+	+							8 h	6 m	2 d	8 h		See also morphine	275
Osmolality	+	+								3 m	1 d	3 h			253, 289

Samples										Stability					
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citrat Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	References
					Hep	EDTA	Citrat			-20°C	4-8°C	20-25°C			
Osteocalcin	+	+	⊕*					min	15 min	8 w (-30 °C)* 1 y***	2 d, 4 d**	8 h, 2 h**	*Aprotinin 2500 KIU/mL + EDTA (5mmol/L)	Three freezing/thawing cycles are possible. ***N-MID-osteocalcin in EDTA plasma	56, 146, 281
Pancreatic elastase	+		+	+						6 m	2 w				
Pancreatic polypeptide	+	+	+								6 d	2 d			64
Paracetamol	+	+	+	(+)				1-4 h	8 h	45 d	2 w	8 h			65, 274, 275, 290
Parathyrin (PTH)	+k ↘	+γ,κ	⊕	(+)γ				3-4 min	6 h (2-3 d in EDTA-blood)	4 m	1 d	6 h	EDTA	15% lower concentrations in serum compared to EDTA plasma.	151, 212
Partial thromboplastin time (aPTT)	-	-	-	⊕					1 d	1 m	2-8 h	2-8 h		Stability reduced in plasma of heparinised patients	1, 2, 38, 105, 134, 256, 292
Parvovirus B 19 – antibodies (erythema infectiosum) – DNA amplification	+														
Phencyclidine	+														
Phenobarbital	+	+	+	(+)β,γ,δ				2-6 d	2 d	6 m	10 d	1 d			36, 65
Phenytoine	+	+ -α -α,Ω	+β,γ,δ, -α,γγ,Ω	(+)β,γ				1-8 d	2 d	5 m	1 m	2 d		Unstable in serum separator tubes (36), but stable in SSTII tubes (30). Biological half-life shorter in children.	30, 36, 65, 290
free	+	+γγ		+α											
Phosphate, inorganic	(+)↗	⊕	-α, γγ,Ω +μ	(+)μ, -α				min	1-16 h↗↗	1 y	7 d	3 d		Platelet-dependent in Serum (163).	27,106,163, 271, 289
Polio virus 1, 2, 3 – antibodies	+													Neutralisation test	
Potassium (K)	(+)↗	⊕	-	-	+			min	1-16 h↗↗	1 y	6 w	6 w		Platelet-dependent in serum >plasma (96, 163, 271), haemolysis↗.	27,57,99, 106, 163, 271, 289
Preatbumin														see Transthyretine	
Primidone	+	+	+	(+)				4-19 h	1 y	5 m	4 w				65
Procainamide and N-acetylprocainamide (NAPA)	+	+β,γγ	+β,γ	(+)β				3-5 h 6-10 h		6 m	2 w				65, 254
Procalcitonin	+	+δ	+	(+)				20-26 h	1-2 d		4 d	4 h			168, 245
Procollagen type I and its N-terminal propeptide (PINP)	+	+	+							1 y	2 d	1 d			100
Pro-gastrin releasing peptide (proGRP)									7 d			7 d		see Gastrin releasing peptide	246
Progesteron	+	+β,-α, μ↘	+β,μ,-α						7 d	1 y	4 d	1 d			51, 289

Samples										Stability					
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citrate Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	References
					Hep	EDTA	Citrat			-20°C	4-8°C	20-25°C			
Proinsulin	+↘	+	⊕					15 min	2 d*	6 m	1 h	7 min	EDTA	*in EDTA	79, 100, 193
Prolactin	+	+β,δ,μ	+β,μ	-					2 d	1 y	6 d	5 d			51, 64, 289
Propafenone	+	+													
Propoxyphene	+	+													
Prostate specific antigen (PSA) - free - total	+ +	+γ +γ,μ,-α	+γ +γ,μ,-κ	(+)γ				2 h 2-3 d	2 h-7 d 4-7 d	1 m↗ 3 m- 2 y	1 d 30 d	6 h 7 d		Three freezing thawing cycles possible.	34, 121, 152, 187, 188, 203, 217, 225, 285
Protein, total	+↘	⊕	+γ,γγ,δ,Ω	(+)				Complex	1 d	1 y	4 w	6 d		Plasma results higher due to fibrinogen (Biuret method).	253, 289
Protein C	-	-	-	⊕				6-8 h	1 w	3 m	7 d	7 d		Avoid freezing/thawing cycles.	105, 162, 292
Protein S	-	-	-	⊕				24-58 h	4 h	1 m	4 h	8 h		Separate cell-free plasma directly after centrifugation.	20, 105
Protein S100	+							2-5 h			7 d	7 d			246
Prothrombin time (Thromboplastin time, Quick)	-	-	-	⊕					4 h-1 w*	1 m	8 h- 1 d*	4 h- 1 d*		*Reagent-dependent	1, 2, 105, 198, 253, 256, 292
Pyruvate	-↘	-↘	-	-	+	*			< 1 min*					*Only stable in deproteinised blood	
Quinidine	+	+β,γγ	+β	(+)β				6-9 h		1-2 w	1 d				65, 274
Renin	-	-	⊕	-					Unstable	1 y		1 h			254
Reovirus antibodies	+														
Respiratory syncytial virus (RSV) antibodies	+														
Reticulocyte count maturity index					(+)	⊕		12 h	3 d* 1 d*		1 d* 1 d*			*EDTA blood	33, 159, 206
Retinol binding protein (RBP)	+	+						10 h		3 m	1 w	4 h			50, 145, 222
Rheumatoid factors subfractions IgA, IgG	+ +	(+)γ,+Ω	(+)γ,+Ω	(+)γ					6 h	3 m	8 d	1 d			151, 289, 290
Rickettsia antibodies	+														
RNA analysis by amplification (PCR)	(+)	-*	+		-*	⊕	+		2 h, 12 h (4°C) 4 d (EDTA) 1 m**	1 y	1 d	< 1 h	5 mmol/L Guanidinium-isothiocyanate **PAXgene™	*Heparin inhibits Taq polymerase and restriction enzymes LiCl 1.8 mol/L eliminates this error (122, 181)	111, 122, 195, 263
Rotavirus antibodies	+														
Rubella virus - antibodies - RNA amplification	+	+β,σ	+β,σ	(+)β,σ		⊕									

Samples										Stability					References
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citrate Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	
					Hep	EDTA	Citrat			-20 °C	4-8 °C	20-25 °C			
S100 protein	+							2-5 h			7 d	7 d		see Protein S 100	246
Salicylate	+	+	+	(+)				24*-30 min		6 m	2 w	7 d		*Higher at toxic concentrations	65, 274
Sandfly (pappataci-) fever antibodies	+														
Selenium (Se)	-	-	-	-		+	*		2 d	1 y	2 w	1 w		*Special tubes, contamination	218
Sirolimus						⊕			1 d* (4-8 °C)	30 d	7 d	8 h	*EDTA-blood	LC-MS/MS	221
Sodium (Na)	+	+	-	-	+	*		min	4 d	1 y	2 w	2 w		*Use 140 mol/L Na-stabilized heparin 8-12 IU/mL blood (29).	57, 106, 289
Soluble transferrin receptor (sTfR)	+	+γ, γγ, ε	-ε						2-6 h	3 m	7 d	3 d		Freeze only once	48, 145, 151, 253, 290
Somatotropin (STH), (growth hormone)	+	+	⊕					20-50 min	1 d	3 m	8 d	3 d	EDTA		51, 64, 289
Squamous cell carcinoma antigen (SCCA)	+	+						1,5-3 h	7 d	1 m	1 m	7 d	Closed tubes	*Increase by contamination (skin)	179, 217, 248
Staphylococcal antibodies - antistaphylococcal antibodies	+	+γ	+γ												
Streptococcal antibodies - anti DNase B	+	+	+						1 h	>1 m	3 d				100
- antihyaluronidase	+	+β, γ, δ	+β, γ, δ												
- antistreptolysin O	+	+β, γ, δ	+β, γ, δ												
- antistreptokinase	+														
Tacrolimus	-	-	-	-	-	⊕		6-21 h	7 d	1 y	2 w	7 d		LC-MS/MS	7, 100, 274
Tartrate-resistant acid phosphatase (TRACP 5b)	+	+	+						2 h	2 m		4 h			100
Testosterone	+	+	+	(+)γ					7 d 1 d in women	1 y	7 d	1 d			51, 132, 271
Tetrahydrocannabinol carboxylic acid (THC)	+	+						~45 h		6 m	6 m	2 m	Na azide	Unstable in plastic tubes.	65, 155
Theophylline	+	+	+	(+)α, β				3-12 h		3 m	7 d	8 h			65, 264, 274
Thrombin time	-	-	-	⊕					1-4 h	1 m	1 h-2 d*	1-4 h*		*Stability reagent- and heparin-dependent.	38, 105, 256, 259
Thrombocyte antibodies	+		+	+											
Thrombocyte count					(+)Δ	⊕	(+)	9-10 d	4 d*, 7 d (4-8 °C)*				*in EDTA blood	Aminoglycosides avoid pseudothrombocytopenia in EDTA (214).	105, 107, 160, 214
Thrombocyte volume						⊕									
Thrombocyte function using platelet function analyzer (PFA) (ε) using flow cytometry	-	-	-	-		⊕		9-10 d	4 h 2 h (7 d*)			1 h		*Special stabiliser recommended (211).	211, 219

Samples										Stability					
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citratd Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	References
					Hep	EDTA	Citrat			-20 °C	4-8 °C	20-25 °C			
Thyroglobulin	+							1 d	2 d	1 m	3 d – 3 w	1 d		Three freezing/thawing cycles possible (45).	45, 253, 289
Thyrotropine (TSH)	+	+β,γ,μ, -α	+α,β,γ,-μ	(+)γ				min	7 d	3 m	3 d	1 d		Spot blood on filter paper in newborns.	51, 271, 289
Thyrotropine receptor-antibodies (TRAb)	+														
Thyroid antibodies Thyroid peroxidase antibodies (TPO), Thyroglobulin antibodies(anti-Tg ^{ab})	+	+									2 d				100
Thyroxine (T ₄)	⊕	+β,γ,γγ, -α,μ	+β,γ,γγ, -α,μ	(+)γ				6 m	7 d	1 m	7 d	5 d			51, 271, 289
Thyroxine, free (fT ₄)	+	+	+	(+)γ					6 h	3 m	8 d	2 d			151, 289
Thyroxine binding globulin (TBG)	+	+							7 d	1 m	5 d	5 d			57, 254, 289
Tick borne encephalitis virus antibodies	+		(+)												
Tobramycin	+	+β,γ,δ	+δ	(+)β				0.5-3 h (<30 y of age) 1.5-15 h (>30 y of age)		1 m	3 d	<2 h		Lower results obtained in heparinised plasma.	65, 207, 274
Toxoplasma gondii antibodies (IgA, IgG, IgM)	+	+β,σ	+β,σ	+β,σ							8 d	8 d			
Transferrin	+	+	+					7-10 d	11 d 3 w (2-6 °C)	6 m - 2 y	8 m	4 m			84,145,258, 271, 289
Transthyretine (prealbumin)	+	+γ,ε	+γ					≈2 d		1 y	6 m	3 d			222
Treponema pallidum antibodies – DNA amplification	+	+σ	+σ	+σ											
Tricyclic antidepressants	+	+β	+β	(+)β					1 w	1 y				see also Amitriptyline	47, 275
Triglycerides	+	+	+,-α	(+)				3 h-3 d	7 d*	y	7 d	2 d		*Decrease of triglycerides, increase of free glycerol, but only minor increase of total glycerol.	44, 106, 271, 289
Triiodothyronine (T ₃)	⊕	(+)β β,γ,δ,μ	+μ					19 h		3 m	8 d	2 d		Serum-plasma difference method dependent	271, 289
Triiodothyronine, free (fT ₃)	+	+	+	(+)γ						3 m	2 w	2 d			82,271,289
Troponin I	+	+β,δ,-α, μ	+δ,-α,μ			+		2-4 h		4 w	3 d	2 d			17, 80, 104, 165, 189, 247
Troponin T	+	+γ	+γ					2-4 h	8 h	3 m	7 d	1 d			80, 165, 247, 253
Tumor necrosis factor (TNF)	-		⊕						1 h				EDTA		54, 69
Urea	+	+	+					min	1 d*	1 y	7 d	7 d		Do not use NH ₄ -heparin.	106, 289, 290, 291
Uric acid	+	+	+Δ	(+)				min	3-7d*	6 m	7 d	3 d			27, 271, 289, 290

Samples									Stability						
Analytes	Serum	Heparinate Plasma	EDTA Plasma	Citrate Plasma	Whole blood			Biological half-life	Stability in blood at room temperature	Stability in serum/plasma			Stabiliser	Remarks/Comments	References
					Hep	EDTA	Citrat			-20 °C	4-8 °C	20-25 °C			
Valproic acid	+	+	+	(+)β				8-15 h	2 d	3 m	7 d	2 d			36, 65
Vancomycin	+	+	+	(+)β				4-10 h		7 d	1 d	2 d			65, 269, 274, 290
Varicella Zoster virus – antibodies – DNA amplification	+	+σ	+σ	+σ			⊕								
Vasoactive intestine polypeptide (VIP)	↘	↘	⊕							>6 d	6 d	1 d	EDTA + aprotinin		64, 178
Vasopressin (ADH)	↘	+	⊕								6 d	1 d	EDTA	Freeze plasma	64
Vitamin A (retinol)	+		⊕					11 h	1 h	2 y	1 m	8 h		light sensitive	100, 253
Vitamin B ₁ (thiamin)	+	+	+				⊕		5 h*	1 y	1 d*	5 h*		light sensitive, *in EDTA blood	100, 116
Vitamin B ₂ (riboflavin)		+	+				⊕		1 h	1 m	1 d*	5 h*		light sensitive, *in EDTA blood	100
Vitamin B ₆ (pyridoxal phosphate)	(+)		⊕				⊕		1 d*	30 d*	3 d*	1 d*	EDTA, darkness	light sensitive, *in EDTA blood, Plasma, Serum	100, 116
Vitamin B ₁₂ (cobalamin)	+	+	⊕						6 h	8 w	1 d	15 min	EDTA, darkness		100, 142, 151
Vitamin C (ascorbic acid)	+	+	+						3 h (4 °C)	3 w*	3 h		60 g/L metaphosphate, deproteinised	*Only with stabiliser	100
Vitamin D 1,25-dihydroxy-vitamin D (calcitriol), 25-hydroxy-vitamin D (calcidiol)	+	+	+						3 d	1 y	7 d	3 d		*Calcidiol light sensitive	100, 253, 275d, 289
Vitamin E (tocopherol)	+		⊕						8 h↘	1 y	1 m	8 h	EDTA		100, 253
Vitamin K (transphylochinone)			+						unstable	3 m	unstable			UV light↘	100, 253
von Willebrand factor			⊕						1 w						292
Yersinia enterocolitica antibodies	+														
Zinc (Zn)	-	+	-	-					30 min↗	1 y	2 w	1 w		Special tube, avoid contamination by stopper.	218, 271, 289

6.2 Urine

Urine

Analyte	Stability in urine at			Stabiliser	Comments	Reference
	-20 °C	4-8 °C	20-25 °C			
Albumin	6 m	1 m	7 d			110, 148, 250, 251
Aluminium	1 y	7 d	3 d			218
5 (δ)-Aminolevulinic acid	1 m	4 d	1 d	pH 6-7, stabilised with 0,3% NaHCO ₃	Drugs ↗ Light ↘	253, 289
Amphetamine	1 y					53
Amylase	> 3 w	> 10 d	2 d		Saliva contaminates ↗ ↘	161
Bence Jones protein (immunoglobulin light chains κ, λ)	6 m	1 m	7 d			250, 251
Calcium	> 3 w	4 d	2 d	Acidify, pH < 2	Crystallisation at cool temperature	42
Catecholamines Norepinephrine Epinephrine Dopamine	Unstabilised 20 d Stabilised 1 y	4 d	4 d 3 w	Acidify pH < 2,5-5 (9 mL 20% HCl in 24 h urine) or EDTA (250 mg/L) and sodium metabisulfite (250 mg/L)		26, 172, 278
Citrate	4 w*		1 d*	*pH < 1,7	*Unstable in native urine	108
Cocaine metabolite Benzoylcegonine	4 m	3 w		pH 5, ascorbic acid		53, 109, 155
Codeine	1 y					53
Copper	1 y	7 d	3 d			218
Cortisol, free	1 w	1 w	2 d	10 g/L boric acid		42, 126, 276
C-peptide		6 d	19 h			64
Creatinine	6 m	6 d	2 d			42, 253
Cystine (Cysteine)	> 1 y*	3 m*	7 d*	*Stabilized in HCl		108
Ethanol		30 d				83, 155
Glucose	2 d	2 h ↘	2 h ↘	10 mmol/L Azid	Bacteria decrease stability	42, 253, 254
5-Hydroxyindoleacetic acid	2 d	2 d	2 h	Acidity		253, 289
Hydroxyproline	5 d	5 d	5 d			253
Immunoglobulin G (IgG)	Unstable	1 m	7 d			110, 148, 250, 251
Iron	> 1 y	7 d	3 d			42
Lysergic acid diethylamide(LSD)	2 m	1 m	1 m	HCl 1 Vol%		53, 155
α ₂ -Macroglobulin		7 d	7 d			
Magnesium	1 y	3 d	3 d	Acidify pH < 2		42, 108
Melanephrienes			8 d			278
α ₁ -Microglobulin	6 m	1 m	7 d			110, 148, 250, 251
Morphine	1 y					53, 65, 155
Myoglobin	> 12 d*	12 d*	12 d*	*pH > 8.0	Unstable at acid pH	286
N-Acetyl-β, D-glucosaminidase (β-NAG)	1 m	7 d	1 d			166
Neutrophil gelatinase associated lipocalin (NGAL)		7 d	1 d			
N-telopeptides (NTx)	4 w	5 d				
Osmolality	> 3 m	7 d	3 h			42
Oxalate	4 m (at pH 1.5)	unstable ↘	< 1 h	pH < 2, HCl 1 Vol %, Thymol 5 mL/L	Vitamin C ↗	108
pH		unstable ↗	unstable ↗		Increase by NH ₄ formation	42
Phosphate, inorganic		6 m < pH 5	2 d at pH < 5.0	1 vol % thymol, 5 mL/L, pH < 5	precipitates at alkaline pH	42, 108

Analyte	Stability in urine at			Stabiliser	Comments	Reference
	-20 °C	4-8 °C	20-25 °C			
Porphobilinogen	1 m*	7 d*	4 d*	*pH 6-7 by NaHCO ₃	Acid pH↘, Light↘	253, 289
Porphyrines Total porphyrine, Uroporphyrine, Heptacarboxyporphyrine, Hexacarboxyporphyrine Pentacarboxyporphyrine, Coproporphyrine Tricarboxyporphyrine, Dicarboxyporphyrine	1 m*	7 d*	4 d*	*0,3% NaHCO ₃ , pH 6-7	Light↘	100, 253
Potassium	1 y	2 m	45 d			42
Protein	1 m	7 d	1 d			42
Pyridinolines	> 1 y	1 w	3 d		UV-Light↘	100, 273, 281
Sediment of urine Acanthocytes Bacteria Epithelial cells Erythrocytes Leukocytes Casts (hyaline and others)		1-8 h 2 d 24 h↗	1-2 h 1 d* 1-2 h↗*** 3 h 1 h, 24 h* 24 h** < 1 h↘*** 2 d	Osmolality >300 mosmol/kg	*>300 mosmol/kg **pH <6,5 ***pH >7,5 Do not freeze	42, 136, 138
Sodium	1 y	45 d	45 d			42
Test-strip fields Erythrocytes Leukocytes Nitrite Protein		1-3 h 1 d* 8 h	4-8 h 1 d* 4 h 2 h**		*>300 mosmol/kg **Unstable at pH 7,5	42, 136, 138
Transferrin	4 w	1 w	7 d			148
Urea	4 w	7 d	2 d	pH < 7		42
Uric acid	unstable		4 d	pH >8	Precipitation at pH <7	42, 108
Vanillyl mandelic acid (VMA)	> 1 y	>7 d	7 d at pH 3-5	pH <5		42, 253, 289

6.3 Cerebrospinal Fluid (CSF)

Analyte	Stability in urine at			Stabiliser	Comments	Reference
	-20 °C	4-8 °C	20-25 °C			
Albumin	>1 y	2 m	1 d	Up to 1 h: Do not cool Up to 3 h: Transport on ice No additives No partial fixation Long term storage: Immediately -70 °C in glass or polypropylene vessels tightly closed.	Glucose, lactate: Stability depends on cell content. IgG: Freezing is not recommended. Leukocytes: Store cells as dry smears.	130, 131
Glucose	>1 m	3 d	5 h↘			
IgA , IgG, IgM	unstable	7 d	1 d			
Lactate	m	1 h	30 min↗			
Leukocytes		3-5 h	1-2 h			
Myeline basic protein (MBP)		2 w	2 d			
Neuron specific enolase (NSE)	1 m, 6 m (-80°C)					
Protein, total	> 1 y	6 d	1 d			197
Tumor cells		1-12 h			Store cells as dry smears.	130, 131

7. References

- Adcock D, Kressin D, Marlar RA. Effects of 3.2 % vs. 3.8 % citrate concentration on routine coagulation testing. *Am J Clin Pathol* 1997; 107: 105-10.
- Adcock D, Kressin D, Marlar RA. The effect of time and temperature variables on routine coagulation tests. *Blood Coagul Fibrinolysis* 1998; 9: 463-70.
- Agness ST, Spierlo FW, Hannon WH. Evaluation of four reagents for lipid dilution of serum. *Clin Biochem* 1983; 16: 98-100.
- Alber B, Mühlbayer D. Wichtige Einflussgrößen und Störfaktoren für die Beurteilung von Tumormarkerkonzentrationen. *Der Bay Int* 2004; 24: 136-40.
- Allura BT, Shirey TL, Young CC, Dell'Orfano K, Hill J, Welsh R, Yeh Q, Barbour RL, Allura B. Characterization of a new ion selective electrode for ionized magnesium in whole blood, plasma, serum, and aqueous samples. *Scand J Clin Lab Invest* 1994; Suppl 217: 21-36.
- Andersson A, Lindgren A, Hullberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. *Clin Chem* 1995; 41: 361-6.
- Annesley TM, Hunter BC, Fidler DR, Giachero DA. Stability of tacrolimus (FK 506) and cyclosporin G in whole blood. *Therap Drug Monit* 1995; 17: 361-5.
- Artiss JD, McEnroe RJ, Zak B. Bilirubin interference in a peroxidase-coupled procedure for creatinine eliminated by bilirubin oxidase. *Clin Chem* 1984; 30: 1389-92.
- Artiss JD, Zak B. Problems with measurements caused by high concentrations of serum lipids. *CRC Crit Rev Clin Lab Sci* 1987; 25: 19-41.
- Astles R, Williams CP, Sedor F. Stability of plasma lactate in vitro in the presence of antilycolytic agents. *Clin Chem* 1994; 40: 1327-30.
- Aufenanger J, Zawta B. Preanalytical aspects of lipoprotein measurement. *Clin Lab* 1999; 45: 535-46.
- Balistreri WF, Shaw LM. Liver function. In: Tietz NW, ed. *Fundamentals of Clinical Chemistry*. Philadelphia: Saunders, 1987 3rd ed., 729-67.
- Banfi G, Salvagno GL, Lippi G. The role of ethylene-diamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes. *Clin Chem Lab Med* 2007; 45: 565-76.
- Banks RE. Measurement of cytokines in clinical samples using immunoassays: Problems and pitfalls. *Crit Rev Clin Lab Sci* 2000; 37: 131-82.
- Bargnoux AS, Dupuy AM, Biron-Andréani C, Schved JF, Cristol JP. Immunonephelometric determination of fibrinogen on citrated or heparinized plasma: comparison with functional Claus method. *Clin Lab* 2005; 51: 285-8.
- Bauer K. Determination of free haemoglobin in serum by automated assay using 4-aminophenazone and the Cobas Bio system. *Clin Chem Clin Biochem* 1981; 19: 971-6.
- Baum H. Kardiale Troponine - Bedeutung der Präanalytik und Analytik für die Diagnostik von Herzmuskelschädigungen. *Der Bay Int* 2004; 24: 141-6.
- Baum H, Bookslegers P, Steinbeck G, Neumeier D. A rapid assay for the quantification of myoglobin: evaluation and diagnostic relevance in the diagnosis of acute myocardial infarction. *Eur J Clin Chem Clin Biochem* 1994; 32: 853-8.
- Beauleu M, Lapointe Y, Vinet B. Stability of pO₂, pCO₂ and pH in fresh blood samples stored in a plastic syringe with low heparin in relation to various blood-gas and hematological parameters. *Clin Biochem* 1999; 32: 101-7.
- Becker B, Denzler B, Kolde HJ, Ramirez J, Rombach B, Strauß J. Fehlermöglichkeiten bei Hämostasetests, Teil 1: Präanalytik, Reagenzien. *MTA* 1994; 9: 794-800.
- Ben Rayana MC, Burnett RW, Covington AK, Ozorio PD, Fog Anderson N, Jacobs E, et al. IFCC guidelines for sampling, measuring and reporting ionized magnesium in plasma. *Clin Chem Lab Med* 2008; 46: 21-6.
- Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. *Clin Chem* 1999; 45: 1695-707.
- Blank DW, Kroll MH, Ruddle ME, Elin RJ. Hemoglobin interference from in vivo hemolysis. *Clin Chem* 1985; 31: 1566-9.
- Boink ABTJ, Buckley BM, Christiansen TF, Covington AK, Moas AHJ, Müller-Plathe O, et al. IFCC-Recommendations on sampling, transport and storage for the determination of concentration of ionized calcium in whole blood, plasma and serum. *Eur J Clin Chem Clin Biochem* 1991; 29: 767-72.
- Bonini PA, Plebani M, Ceriotti F, Rubboli F. Errors in laboratory medicine. *Clin Chem* 2002; 48: 691-8.
- Boomsma F, Alberts G, van Eijk L, Man in't Feld, Schalekamp MADH. Optimal collection and storage conditions for catecholamine measurement in human plasma and urine. *Clin Chem* 1993; 39: 2503-8.
- Boyanton BL, Blick K. Stability studies of twenty-four analytes in human plasma and serum. *Clin Chem* 2002; 48: 2242-7.
- Brady J, O'Leary N. Interference due to lipaemia in routine photometric analysis - survey of an underrated problem. *Ann Clin Biochem* 1994; 31: 281-8.
- Burnett RW, Covington AK, Fogh-Andersen N, Külpmann WR, Moas AHJ, Müller-Plathe O, et al. Approved IFCC recommendations on whole blood sampling, transport, and storage for simultaneous determination of pH, blood gases, and electrolytes. *Eur J Clin Chem Clin Biochem* 1995; 33: 247-53.
- Bush V, Blennerhassel J, Wells A, Dasgupta A. Stability of therapeutic drugs in serum collected in vacutainer serum separator tubes containing a new gel (SST II). *Ther Drug Monit* 2001; 23: 259-62.
- Caliezi C, Reber G, Lämmle B, de Moerloose P, Willemin WA. Agreement of D-dimer results measured by a rapid ELISA (VIDAS) before and after storage during 24 h or transportation of the original whole blood samples. *Thromb Haemost* 2000; 83: 177-8.
- Collas DD, Clark TL, Moreira PL, Lansden C, Gawryl MS, Kahn S, Bermes EW. In vitro effects of a novel haemoglobin-based oxygen carrier on routine chemistry, therapeutic drug, coagulation, hematology, and blood bank assays. *Clin Chem* 1997; 43: 1741-8.
- Carilli I, Kraajenhagen R, Pradella R, D'Okofrio G, Herkner K, Ravan RM et al. In vitro stability of the reticulocyte count. *Clin Lab Haematol*. 1996; 18: 9-11.
- Cartledge JJ, Thompson D, Verril H, Clarkson P, Eardley I. The stability of free and bound prostate-specific antigen. *Brit J Urol* 1999; 84: 810-4.
- Checkonin VP, Zhirkov YA, Belyoelva A, Ryabakhin IA, Gurina OI, Dimitriyeva TB. Serum time course of two brain specific proteins, alpha (1) brain globulin and neuron-specific enolase, in tickborn encephalitis and Lyme disease. *Clin Chim Acta* 2002; 320: 117-25.
- Chetty M. The stability of anticonvulsant drugs in whole blood. *Ther Drug Monit* 1994; 16: 491-4.
- Chiu RWK, Poon LL, Lan TK, Leung TN, Poon PM et al. Quantitative analysis of fetal and total DNA quantitation in maternal plasma. *Clin Chem* 2001; 47: 1607-13.
- CLSI. Document H21-A5. Collection, transport and processing of blood specimens for testing plasma-based coagulation assays. Approved standard, 5th ed. Wayne, PA, 2007.
- CLSI. Document EP7-P. Interference testing in clinical chemistry; proposed guideline. Wayne, PA, 1986.
- CLSI. Document H3-A6. Procedures for the collection of diagnostic blood specimens by venipuncture. Approved standard, 6th ed. Wayne, PA, 2007.
- Cobbaert C, Tricarico A. Different effects of IntralipidTM and triacylglycerol rich lipoproteins on Kodak Ektachem serum cholesterol determination. *Eur J Clin Chem Clin Biochem* 1993; 31: 107-9.
- Colombo JP (ed.). *Klinisch-chemische Urindiagnostik*. Rotkreuz: LaboLife, 1994.
- Conrad K. Autoimmunerkrankungen. In: Guder WG, Nolte J (Hrsg) *Das Laborbuch für Klinik und Praxis*. 2. Aufl München: Elsevier Urban und Fischer 2009.
- Cooper RG, Sampson EJ, Smith SJ. Preanalytical, including biological variation in lipid and apolipoprotein measurements. *Curr Opin Lipidol* 1992; 3: 365-71.
- Court JJ, Clark PM, Holder G, Sheppard MC. Collection and storage conditions of serum for the analysis of thyroglobulin. *Proc ACB National Meeting*. *Ann Clin Biochem* 2002; Suppl: 36-7.
- Dale JC, Prust SK. Phlebotomy - a minimalist approach. *Mayo Clin Proc* 1993; 68: 249-55.
- Dasgupta A, Yared MA, Wells A. Time-dependent absorption of therapeutic drugs by the gel of Greiner Vacuette blood collection tube. *Ther Drug Monit* 2000; 22: 427-31.
- De Jongh R, Vranken J, Vundelinckx, Bosmans E, Moes M, Heylen R. The effects of anticoagulation and processing on assays of IL-6, sIL-6R, sIL-2R and soluble transferrin receptor. *Cytokine* 1997; 9: 696-701.
- Delanghe JR, Chapelle JP, Vanderschueren SC. Quantitative nephelometric assay for determining myoglobin evaluated. *Clin Chem* 1990; 36: 1675-8.
- Develter M, Blanchaert N, Komárek A, Bossuyt X. Can heparin plasma be used instead of serum for nephelometric analysis of serum proteins. *Clin Chem*. 2006; 52: 1609-10.
- Diver MJ, Hughes JG, Hutton JL, West CR, Hipkin LJ. The long-term stability in whole blood of 14 commonly-requested hormone analytes. *Ann Clin Biochem* 1994; 31: 561-5.
- Dörner K, Böhler H. *Laboridiagnostische Strategien in der Pädiatrie*. Darmstadt: GIT, 1996.
- Dugan S, Bogema S, Schwartz RW, Lappas NT. Stability of drugs of abuse in urine samples stored at -20 °C. *J Anal Toxicol* 1994; 18: 391-6.
- Dugue B, Leppänen E, Gräsbeck R. Preanalytical factors and the management of cytokines in human subjects. *Int J Clin Lab Res* 1996; 26: 99-105.
- Duncanson GO, Worth HGJ. Pseudohyphosphataemia as a result of bilirubin interference. *Ann Clin Biochem* 1990; 27: 263-7.
- Durham BH, Robinson J, Fraser WD. Differences in the stability of intact osteocalcin in serum, lithium heparin plasma and EDTA plasma. *Ann Clin Biochem* 1995; 32: 422-3.
- Einer G, Zawta B. *Präanalytik-Fibel*. 2nd ed, Leipzig, Heidelberg: Barth, 1991.
- Engstad CS, Guttenberg TJ, Osterud B. Modulation of blood cell activation by four commonly used anticoagulants. *Thromb Hemost* 1997; 77: 690-6.
- Ernst DJ, Szamosi DI. Specimen collection standards complete major revisions. *Med Lab Observ* 2005; 37: 26-9.
- Erwa W, Bauer FR, Etschwaiger R, Steiner V, Scott CS, Sedlmayr P. Analysis of aged samples with the Abbott CD 400 hematology analyzer. *Eur J Lab Med* 1998; 6: 4-15.
- Erickson JA, Ashwood EA. Evaluation of a myelin basic protein (MBP) assay and the identification of highly elevated MBP in demyelinating disorders. *Clin Chem*. 2003; 43: A108 (abstract).
- European IVD Directive for in vitro diagnostics. Amsblatt der Europäischen Gemeinschaften L331/1 vom 7.12.1998.
- Evans K, Mitcheson J, Laker MF. Effect of storage at 4 °C and -20 °C on lipid, lipoprotein, and apoprotein concentrations. *Clin Chem* 1995; 41: 392-6.
- Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. *Clin Biochem* 2000; 34: 107-12.
- Evans WE, Oellerich M, Holt DW. Drug monitoring. Leitfaden für die klinische Praxis, 2nd ed. Wiesbaden: Abbott Diagnostics Division, 1994.
- Faynor SM, Rosbinson R. Suitability of plastic collection tubes for cyclosporin measurements. *Clin Chem* 1998; 44: 2220-1.
- Fiedler GM, Thiery J. Der "fehlerhafte" Laborbefund: 1. Fehlerquellen der prä- und postanalytischen Phase. *Internist* 2004; 45: 315-32.
- Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cyslatin C measurement by particle-enhanced immunonephelometry of the Behring nephelometer systems (BNA, BNI). *Clin Chem* 1997; 43: 1016-22.
- Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V. Effects of sample handling on the stability interleukin 6, tumor necrosis factor alpha and leptin. *Cytokine* 2000; 12: 1712-6.
- Fonseca-Wallheim F da. Ringstudie zur Bilirubininterferenz bei der Bestimmung von Serum-Kreatinin. *Laboratoriumsmedizin* 1988; 12: 317-20.
- Fonseca-Wallheim F da. Ultrafiltrate analysis confirms the specificity of the selected method for plasma ammonia determination. *Eur J Clin Chem Clin Biochem* 1992; 30: 15 9.
- Fonseca-Wallheim F da. Deamidation of glutamine by increased plasma γ -glutamyltransferase is a source of rapid ammonia formation in blood and plasma specimens. *Clin Chem* 1990; 36: 1479-82.
- Fonseca-Wallheim F da, Heinze KG, Lamsky K, Schreiner H. Serum ultrafiltration for the elimination of endogenous interfering substances in creatinine determination. *J Clin Chem Clin Biochem* 1988; 26: 523-5.
- Fuentes-Arderiu X, Fraser CG. Analytical goals for interference. *Ann Clin Biochem* 1991; 28: 393-5.
- Gambino R, Piscitelli J, Ackoffupathil TA, Theriault JL, Andrin RD, Sanfilippo ML, Elenne M. Acidification of blood is superior to sodium fluoride alone as an inhibitor of glycolysis. *Clin Chem* 2009; 55: 1019-21.
- Gamsjäger T, Brenner L, Siltzwohl C, Weinstall C. Half-lives of albumin and cholinesterase in critically ill patients. *Clin Chem Lab Med* 2008; 46: 1140-2.
- Garb S. *Clinical guide to undesirable drug interactions and interferences*. New York: Springer, 1971.

78. Gaze DC, Crompton L, Collison PO. Sample stability of ischaemia modified albumin (IMATM) as assessed by the albumin cobalt binding (ACB®) test. *Clin Chem* 2003; 49: A40 (abstract).
79. Gerbitz KD. Pankreatische B-Zellenpeptide: Kinetik und Konzentration von Proinsulin, Insulin und C-Peptid in Plasma und Urin. Probleme der Meßmethoden, klinische Aussage und Literaturübersicht. *J Clin Chem Clin Biochem* 1980; 18: 313-26.
80. Gerhardt W, Nordin G, Herbert AK, Burzell BL, Isaksson A, Gustavsson E, et al. Troponin T and I assays show decreased concentrations in heparin plasma compared with serum: lower recoveries in early than in late phases of myocardial injury. *Clin Chem* 2000; 46: 817-21.
81. Giampetro O, Navalesi R, Buzzigoli G, Boni C, Benzi L. Decrease in plasma glucose concentration during storage at -20 °C. *Clin Chem* 1980; 25: 1710-2.
82. Giovannino D, Fortunato A, Barzon E, Church S, Bérubé J, Green S, Soffoli G. Evaluation of BD vacutainer® PSTTM II tubes for a wide range of immunoassays. *Clin Chem Lab Med* 2009; 47: 237-41.
83. Gibitz HJ, Schütz H. Bestimmung von Ethanol im Blut. Mitt XX der Senatskommission für klinisch-toxikologische Analytik. Weinheim: VCH Verlagsgesellschaft, 1993.
84. Gislefoss RE, Grimsrud TK, Morkrid L. Stability of selected serum proteins after long term storage in the Janus Serum Bank. *Clin Chem Lab Med* 2009; 47: 596 – 603.
85. Glick MR, Pieper J, Ryder KW. Interference-reduced methodologies for Boehringer Mannheim/Hitachi analyzers: validation using recombinant haemoglobin „blood substitute“ product. *Clin Chem* 1998; 44, Suppl. A 140.
86. Glick MR, Ryder KW, Glick SJ. Interferographs. Evaluation. 2nd ed Indianapolis: Sciences Inc., 1991.
87. Goosens W, van Duppen V, Verwilghen RL. K2- or K3-EDTA: the anticoagulant of choice in routine haematology? *Clin Lab Haemat* 1991; 13: 291-5.
88. Grafmeyer D, Bondon M, Manchon M, Levillain P. The influence of bilirubin, haemolysis and turbidity on 20 analytical tests performed on automatic analysers. *Eur J Clin Chem Clin Biochem* 1995; 33: 31-52.
89. Grasseil M, Platen U, Zawta B. Erfahrungen mit Venenblut in der ambulanten hämatologischen Routinediagnostik. *Dtsch Ges Wesen* 1972; 27: 1844-7.
90. Gravina P, Ciotti M, Masini S, Valentini A, Marcucilli F, Croce N, et al. Impact of storage conditions on genetic analysis of viral load determination in clinical specimens. *Clin Chem Lab Med* 2008; 46: 280-2.
91. Gross J, Ungelhüm U, Moller R, Priem F, Heldt J, Ziegler R, et al. Analytical factors influencing the measurement of NSE levels in blood. *J Lab Med* 1995; 18: 286-9.
92. Guder WG. Haemolysis as an influence and interference factor in clinical chemistry. *J Clin Chem Clin Biochem* 1986; 24: 125-6.
93. Guder WG (administrator) www.diagnosticsample.com
94. Guder WG, da Fonseca-Wollheim F, Heil W, Müller-Plathe O, Töpfer G, Wisser H, et al. Stabilität der Maßgrößen in der Probenmatrix. *Klin Chem Mitt* 1995; 26: 205-24.
95. Guder WG, da Fonseca-Wollheim F, Heil W, Müller-Plathe O, Töpfer G, Wisser H, et al. Wahl des optimalen Probenvolumens. *Klin Chem Mitt* 1996; 27: 106-7.
96. Guder WG, Ehrel W, da Fonseca-Wollheim F, Heil W, Müller-Plathe O, Töpfer G, et al. Serum, plasma or whole blood? Which anticoagulants to use? *Lab Med* 1998; 22: 297-312.
97. Guder WG, da Fonseca-Wollheim F, Heil W, Schmitt Y, Töpfer G, Wisser H, et al. The haemolytic, icteric and lipemic sample. Recommendations regarding their recognition and prevention of clinically relevant interferences. *J Lab Med* 2000; 24: 357-64.
98. Guder WG, da Fonseca-Wollheim F, Heil W, Schmitt Y, Töpfer G, Wisser H, et al. Die Qualität diagnostischer Proben. BD-Diagnostics, Heidelberg 2009.
99. Guder WG, Narayanan S, Wisser H, Zawta B. Diagnostic Samples: From the Patient to the Laboratory, 4th ed. Weinheim: Wiley-Blackwell, 2009.
100. Guder WG, Nolle H. Das Laborbuch für Klinik und Praxis, 2nd ed. München: Elsevier Urban und Fischer 2009.
101. Hagemann P. Qualität im Arztlabor. Optimierung der Präanalytik. Heidelberg: Springer, 1994.
102. Hallbach J, Hoffmann GE, Guder WG. Overestimation of albumin in heparinized plasma. *Clin Chem* 1991; 37: 566-8.
103. Hauswaldt C, Schröder U. Differentialblutbilder im EDTA-Blut. Fehlermöglichkeiten und Grenzen. *Di Med Wschr* 1973; 98: 2391-7.
104. Heeschen C, Goldmann BU, Langenbrink L, Matschuk G, Hamm CW. Evaluation of a rapid whole blood ELISA for quantification of troponin I in patients with acute chest pain. *Clin Chem* 1999; 45: 1789-96.
105. Heil W, Grunewald R, Amend M, Heins M. Influence of time and temperature on coagulation analytes in stored plasma. *Clin Chem Lab Med* 1998; 36: 459-62.
106. Heins M, Heil W, Withold W. Storage of serum or whole blood samples? Effect of time and temperature on 22 serum analytes. *Eur J Clin Chem Clin Biochem* 1995; 33: 231-8.
107. Heins M, Schossow B, Greiner L, Heil W. Influence of storage time and temperature on haematological measurands using a Sysmex NE 8000 analyser. *J Lab Med* 2000; 24: 236-42.
108. Hesse A, Claßen A, Röhle G. Labordiagnostik bei Urolithiasis. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1989.
109. Hippenstiel MJ, Gerson B. Optimization of storage conditions for cocaine and benzoylcegonine in urine: a review. *J Anal Toxicol* 1994; 18: 104-9.
110. Hofmann W, Guder WG. Präanalytische und analytische Faktoren bei der Bestimmung von IgG, Albumin, α 1-Mikroglobulin und Retinol-bindendem Protein im Urin mit dem Behring Nephelometer System (BNS). *J Lab Med* 1989; 13: 470-8.
111. Holodniy M. Effects of collection, processing, and storage on RNA detection and quantification. In: Kochanowski B, Reischl U (eds.). *Quantitative PCR-Protocols*. Totowa (USA): Humana Pr, 1999.
112. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves EW, Merigan TC. Inhibition of human immunodeficiency virus gene amplification by heparin. *J Clin Microbiol* 1991; 29: 676-9.
113. Holodniy M, Rainer L, Herman S, Yen-Lieberman B. Stability of plasma immunodeficiency virus load in vacutainer PPT plasma preparation tubes during overnight shipment. *J Clin Microbiol* 2000; 38: 323-6.
114. Huizenga JR, van der Belt K, Gips CH. The effect of storage at different temperatures on cholinesterase activity in human serum. *J Clin Chem Clin Biochem* 1985; 23: 283-5.
115. International council for standardization in haematology. Recommendations of the ICSH for ethylenediamine tetraacetic acid anticoagulation of blood for blood cell counting and sizing. Expert panel on cytometry *Am J Clin Pathol* 1993; 100: 371–2.
116. Ishii H, Sarai K, Sanemori H, Kawasaki T. Analysis of thiamine and its phosphate esters by high-performance liquid chromatography. *Anal Biochem* 1979; 97: 191.
117. ISO/EN/DIN 6710. Single-use containers for human venous blood specimen collection. Geneva/Bruelles/Berlin, 2007.
118. ISO/EN/DIN 15189. Medical laboratories - Particular requirements for quality and competence Geneva/Bruelles/Berlin, 2007.
119. ISO GUIDE 30. Terms and definitions used in connection with reference materials, 2nd ed. Geneva 1992.
120. Johnston A, Cullen G, Holl DW. Quality assurance for cyclosporin assays in body fluids. *Ann Acad Med Singapore* 1991; 20: 3-8.
121. Jung K, Klingroeff P von, Brux B, Sinha P, Schnor L, Loening SA. Preanalytical determinations of total and free prostate-specific antigen and their ratio: blood collection and storage conditions. *Clin Chem* 1998; 44: 685-8.
122. Jung R, Lübcke C, Wogener C, Neumaier M. Reversal of r-PCR inhibition observed in heparinized clinical specimens. *Biotechniques* 1998; 23: 24-8.
123. Kallner A. Preanalytical procedures in the measurement of ionized calcium in serum and plasma. *Eur J Clin Chem Clin Biochem* 1996; 34: 53-8.
124. Kampa JS, Keffer P. Evaluation of the B-type natriuretic peptide (BNP) and pro-brain natriuretic peptide (NT-pro-BNP) in congestive heart failure (CHF) patients. *Clin Chem* 2003; 49: A 32 (abstract).
125. Kazmierczak SC, Catrou PG, Best AE, Sullivan SW, Briley KP. Multiple regression analysis of interference effects from a haemoglobin-based-oxygen carrier solution. *Clin Chem Lab Med* 1999; 37; 453-64.
126. Keiichi M, Suday A, Kawasaki J. Effect of urine pH, storage time and temperature on stability of catecholamines, cortisol, and creatinine. *Clin Chem* 1998; 44: 1759-62.
127. Keller H. Klinisch-chemische Labordiagnostik für die Praxis, 2. Aufl. Stuttgart: Thieme, 1991.
128. Keller RH, Lyman S. α -Fetoprotein: biological and clinical potential. In Rhodes BA (ed.). *Tumor Imaging*. New York: Masson Publ 1982: 41-52.
129. Kendall RG, Chapman C, Hartley AE, Norfolk DR. Storage and preparation of samples for erythropoietin radioimmunoassay. *Clin Lab Haematol* 1991; 13: 189-96.
130. Kleine TO, Boerlacher K, Niederer V, Keller H, Reuther F, Trilschler W, et al. Diagnostische Bedeutung der Lactatbestimmung im Liquor bei Meningitis. *Di Med Wschr* 1979; 104: 553-7.
131. Kleine TO, Hackler R, Lehmitz R, Meyer-Riemecker H. Liquordiagnostik: klinisch-chemische Kenngrößen: Eine kritische Bilanz. *Klin Chem Mitt* 1994; 25: 199-214.
132. Kley HK, Rick W. Einfluß von Lagerung und Temperatur auf die Analyse von Steroiden in Plasma und Blut. *J Clin Chem Clin Biochem* 1984; 22: 371-8.
133. Koch TR, Platoff G. Suitability of collection tubes with separation gels for therapeutic drug monitoring. *Ther Drug Monit* 1990; 12: 277-80.
134. Köhler M, Datt F, Kalde HJ. Aktivierte partielle Thromboplastinzeit (aPTT)-Standardbestimmung - Standardisierung der Methode, Interpretation der Befunde und Grenzen der Anwendbarkeit. *J Lab Med* 1995; 19: 162-6.
135. Koenig I, Skopp G, Aderjan J, Koenig S. Stabilität von Benzodiazepinen in Blut und Plasma bei Licht- und Wärmeexposition. *Klin Paediatr* 1999; 211: 122, Abstr, Nr. V8.
136. Koivula T, Groenroos P, Gävert J, Ioen A, Irjala K, Penttilä I, et al. Basic urinalysis and urine culture: Finnish recommendations from the Working Group on clean midstream specimens. *Scand J Clin Lab Invest* 1990; 50 (suppl. 200): 26-33.
137. Korle W, Riesen WF. Comparability of serum and plasma concentrations of haemostasis. *Clin Chem Lab Med* 2001; 39: 627-30.
138. Kouri T, Fogazzi G, Gant V, Hallander H, Hofmann W, Guder WG. European urinalysis guidelines. *Scand J Clin Lab Invest* 2000; 60 (suppl 231): 1-96.
139. Kramer KA, O'Brien JF, McConnel JP. Oxidized LDL-Evaluation of an ELISA method for potential use as a marker of cardiovascular risk. *Clin Chem* 2003; 49: A168 (abstract).
140. Kreutzer HJH, Paanokker MPWM. Stability of routine chemistry parameters in lithium heparin gel tubes. *Proc 11th Eur Cong Clin Chem*, Tampere 1995, abstr. 357.
141. Külpmann WR. Determination of electrolytes in serum and serum water. *Wiener Klin Wschr* 1992; suppl: 34-8.
142. Kuhl L, Tamm A. On the stability of vitamin B12, folic acid and ferritin in serum. Quality of Preanalytical Phase in Europe. Leuven: Terumo, 2001.
143. Lammers M. Dilution of citrated plasma. *Eur J Clin Chem Clin Biochem* 1996; 34: 369.
144. Lammers M, Gressner AM. Immunonephelometric quantification of free haemoglobin. *J Clin Chem Clin Biochem* 1987; 25: 363-7.
145. Lammers M, Rausch S. Suitability of plasma specimen for immunonephelometric protein assays. *Clin Chem Lab Med* 2002; 40: S114.
146. Lang M, Seibel MJ, Zpf A, Ziegler R. Einfluß eines neuen Proteolysehemmers auf die Haltbarkeit von Osteocalcin im Serum. *Klin Lab* 1996; 42: 5-10.
147. Leary NO, Pembroke A, Duggan PF. Measuring albumin and calcium in serum in a dual test with the Hitachi 704. *Clin Chem* 1992; 38: 1342-5.
148. Ledue TB, Collins MF, Craig WY, Ritchie RF. Effect of storage time, temperature and preservative on IgG, transferrin, albumin and alpha-1-microglobulin levels in urine. *Clin Chem* 2000; 46, Suppl.: A 48 (abstract).
149. Lee JS, Carlton E, Ossalinska-Plewnia J, Lu J. Invasive trophoblast antigen (ITA) testing: sample collection and handling. *Clin Chem* 2003; 49:A127 (abstract).
150. Lefevre GF. Analytical performance of the ACB test for ischaemia on the Konelab20. *Clin Chem* 2003;49: A33 (abstract).
151. Leino A, Koivula MK. Stability of chemical and immunochemical analytes in centrifuged plasma samples. *Ann Clin Biochem* 2009; 46:159-61.
152. Leinonen J, Stenman UH. Reduced stability of prostate-specific antigen after long-term storage of serum at -20 °C. *Tumour Biol* 2000; 21: 46-53.
153. Leonard PJ, Persaud J, Mohwani R. The estimation of plasma albumin by BCG dye binding on the Technicon SMA 12/60. *Clin Chim Acta* 1971; 35: 409.
154. Leppänen E, Gräsbeck R. The effect of the order of filling tubes after venipuncture on serum potassium, total protein, and aspartate and alanine aminotransferase. *Scand J Clin Lab Invest* 1986; 46: 189-91.

155. Levine B, Smith ML. Stability of drugs of abuse in biological specimens. *Forensic Sci Rev* 1990; 2: 148-56.
156. Law J, Reichelderfer P, Fowler M, Bremer J, Carrol R, Casols S, et al. Determination of levels of human immunodeficiency virus Type 1 RNA in plasma: reassessment of parameters affecting assay outcome. *J Clin Microbiol* 1998; 38: 1471-9.
157. Lippi G, Brocco G, Salvagno GL, Montagnano M, Guidi GC, Schmidt Gayk H. Influence of sample matrix on the stability of 6-CTX of room temperature for 24 and 48 hours. *Clin Lab* 2007; 53:455-9.
158. Lippi G, Giampaolo L, Giancresce G. Effect of anticoagulants on lipoprotein(a) measurements with four commercial assays. *Eur J Clin Chem Clin Biochem* 1996; 34: 251-5.
159. Lippi G, Salvagno GL, Solero GP, Franchini M, Guidi GC. Stability of blood cell counts, hematological parameters and reticulocyte indexes on the ADVIA 120 hematological analyzer. *J Lab Clin Med* 2005; 166: 333-40.
160. Maguire GA, Poon R, Lane G, Modena N, Lippi G. EDTA induced platelet aggregation can be avoided by a new anticoagulant platelet for automated blood count. *Haematologia* 1990; 75: 38-41.
161. Lorentz K. Approved Recommendation on IFCC methods for the measurements of catalytic concentration of enzymes. Part 9. IFCC method for α -amylase (1,4- α -D-glucan 4-glycanohydrolase, EC 3.2.1.1). *Clin Chem Lab Med* 1998; 36: 185-203.
162. Luddington R, Peters J, Baker P, Baglin R. The effect of delayed analysis or freeze-thawing on the measurement of natural anticoagulants, resistance to activated protein C and markers of activation of the haemostatic system. *Thromb Res* 1997; 87: 577-81.
163. Lutomski DM, Bower RH. The effect of thrombocytosis on serum potassium and phosphorus concentration. *Am J Med Sci* 1994; 307: 255-8.
164. Maguire GA, Price CP. A continuous monitoring spectrophotometric assay for the measurement of angiotensin-converting enzyme in human serum. *Ann Clin Biochem* 1985; 22: 204.
165. Mair J, Puschendorf B. Aktuelle Aspekte der Labordiagnostik des akuten Myokardinfarktes. *J Lab Med* 1995; 19: 304-18.
166. Matteucci E, Giampetro O. To store urinary enzymes: How and how long? *Kidney Int* 1994; Suppl 47: 58-9.
167. McKenzie D, Henderson A. Electrophoresis of lactate dehydrogenase isoenzymes. *Clin Chem* 1983; 29: 189-95.
168. Meisner M, Tschalkowsky K, Schnabel S, Schmidt BJ, Katalivic A, Schüller J. Procalcitonin - influence of temperature, storage, anticoagulation and arterial or venous osservation of blood samples on procalcitonin concentrations. *Eur J Clin Chem Clin Biochem* 1997; 35: 597-601.
169. Menssen HD, Melber K, Brandt N, Thiel E. The use of hirudin as universal anticoagulant in haematology, clinical chemistry and blood grouping. *Clin Chem Lab Med* 2001; 39: 1267-77.
170. Merve D, Henley R, Lane G, Field R, Frenneaux M, Dunstan F, McDowell I. Effect of different sample types and stability after blood collection of N-terminal pro-B type natriuretic peptide as measured with the Roche Elecsys system. *Clin Chem* 2004; 50: 779-80.
171. Meyer T, Monge PK, Sakshaug J. Storage of blood samples containing alcohol. *Acta Pharmacol Toxicol* 1979; 45: 282-6.
172. Morello R, Boos KS, Seidel D. Standardized preanalytics of urinary marker molecules and on line SPE-LC-ECD analysis of catecholamines in urine and plasma. 2nd Pharmaceutical Sciences World Congress (PSWC) 2004, Kyoto, Japan.
173. Morré SA, Van Valkengoed IGM, De Jong A, Boeke AJP, Van Eijk JTM, Meijer CILM, et al. Mailed, home-obtained urine specimen: a reliable screening approach for detecting asymptomatic Chlamydia trachomatis infections. *J Clin Microbiol* 1999; 37: 976-80.
174. Mößner G. Präanalytik von hämostaseologischen Laboruntersuchungen. *Der Bay Int* 2004; 24: 124-132.
175. Müller T, Gegenhuber A, Dieplinger B, Poetzl W, Haltmayer M. Long term stability of endogenous B type natriuretic peptide (BNP) and amino terminal pro-BNP (NT-proBNP) in frozen plasma samples. *Clin Chem Lab Med* 2004; 42: 942-4.
176. Mussap M, Ruzzante N, Varagnolo M, Plebani M. Quantitative automated particle-enhanced immunonephelometric assay for the routine measurement of human cystatin C. *Clin Chem Lab Med* 1998; 36: 859-65.
177. Nanji AA, Poon R, Hineberg I. Lipaemic interference: Effects of lipaemic serum and Intralipid. *J Clin Pathol* 1998; 41: 1026-7.
178. Narayanan S. Protection of peptidic substrates by protease inhibitors. *Biochim Clin* 1987; 11: 954-6.
179. Narayanan S. Quality control in tumor marker analysis: pre-analytical issues. *J Clin Ligand Assay* 1998; 21: 11-7.
180. Narayanan S. The preanalytical phase. An important component of laboratory medicine. *Am J Clin Pathol* 2000; 113: 429-52.
181. Neumaier M, Braun A, Wagener C. Fundamentals of quality assessment of molecular amplification methods in clinical diagnostics. *Clin Chem* 1998; 44: 12-26.
182. Nilson E, Ekholm B, Rees-Smith B, Tom C, Hillburan M. Calcium addition to EDTA-Plasma eliminates falsely positive results in the RSR GADA by ELISA. *Clin Chim Acta* 2008; 388: 130-4.
183. Nilsson L, Hedner U, Nilsson M, Robertson B. Shelf-life of bank blood and stored plasma with special reference to coagulation factors. *Transfusion* 1983; 23: 377-81.
184. Numata Y, Doki K, Furukawa Akikuoka S, Asada H, Fukunaga T, et al. Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma. *Clin Chem* 1998; 44: 1008-13.
185. Okabe R, Nakatsuka K, Imada M, Miki T, Naka H, Nasaki H, et al. Clinical evaluation of the Elecsys β -crosslamb serum assay, a new assay for degradation products of type I collagen C-telopeptides. *Clin Chem* 2001; 47: 1410-4.
186. Ono T, Kitaguchi K, Takehara M, Shiba M, Hayami K. Serum constituents analysis: effect of duration and temperature of storage of clotted blood. *Clin Chem* 1981; 27: 35-8.
187. Oremek GM, Seiffert UB. Physical activity releases prostate-specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations. *Clin Chem* 1996; 42: 691-5.
188. Ossendorf M, Fichtner J, Schroeder S, Thuroff JW, Pirellwitz W. In vitro Stabilität des freien prostataspezifischen Antigens (PSA) in Serum- und Vollblutproben. *Anticancer Res* 1997; 17: 4199, No 6C, Abstr. No 58.
189. Pai JK, Curhan GC, Cannuscio CC, Rifai N, Ridker PM, Rimm RB. Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. *Clin Chem* 2002; 48: 1781-84.
190. Panfeghini M, Pagoni F. Pre-analytical, analytical and biological sources of variation of lipoprotein (a). *Eur J Clin Chem Clin Biochem* 1993; 31: 23-8.
191. Pararo C, Tagini E, Meda R, Scott CS, Novaro O. Improved stability of leucocytes in aged samples: investigation of an alternative anticoagulant strategy in hematology for use with the Abbott Cell-Dyn CD 3500 hematology analyzer. *Eur J Lab Med* 1998; 6: 16-23.
192. Pfund A, Wendland G, Geisen C, Hoepff HW. Reliability of homocysteine measurement. *Herz/Kreislauf* 1999; 33: 381-5.
193. Plützer A, Plützer AH, Kann PH, Stule R, Löbig M, Yang JM, Mistry J, Forst T. Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin. *Clin Lab* 2005; 51: 243-9.
194. Probst R, Brandt R, Blümke M, Neumeler D. Stabilization of homocysteine concentration in whole blood. *Clin Chem* 1998; 44: 1567-9.
195. Rainen L, Oelmueller U, Jurgensen S, Wyrich R, Ballas C, Schram J, Herchma C et al. Stabilization of mRNA expression in whole blood samples. *Clin Chem* 2002; 48: 1883-90.
196. Rahmali K, Lemmark A, Becker C, Follyn-Zadura A, Larsson K, Ivarson S-A, Tom C. A comparison of serum and EDTA-plasma in the measurement of glutamic acid decarboxylase autoantibodies (GADA) and autoantibodies to islet Antigen 2 (IA-2A) using the RSR radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA) kits. *Clin Chem* 2008; 54: 227-35.
197. Ramont L, Thoannes H, Volandot A, Chastang F, Millet M-C, Marquet F-X. Effects of hemolysis and storage conditions on neuron-specific enolase (NSE) in cerebrospinal fluid and serum, in patients in clinical practice. *Clin Chem Lab Med* 2005; 43: 1215-7.
198. Rao LV, Okorodudu AO, Petersen JR, Elgethay MT. Stability of prothrombin time and activated partial prothrombin time tests under different storage conditions. *Clin Chim Acta* 2000; 300: 13-21.
199. Rasbold K, Rendell MS, Goljan E. Simple removal of lipids from serum. *Clin Chem* 1985; 31: 782.
200. Rasmussen K, Möller J, Lyngbak M, Holm Pedersen AM, Dybkoer L. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. *Clin Chem* 1996; 42: 630-6.
201. Reisch N, Mauracher B, Bidlingmaier M, Reinke M. ACTH stability dependent on different preanalytical procedures. *Exp Clin Endocrinol Diabetes* 2006; 114: S 76-7.
202. Reiter W, Göhring P, Stieber P, Pahl H, Kempler B, Banauch D. The influence of blood taking, storage conditions and interfering factors on a new fibrin monomer test. *J Lab Med* 1996; 20: 112-6.
203. Richardson TD, Wojno KJ, Liang LW, Giachero DA, England BG, Henricks WH, et al. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy. *Urology* 1996; 48: 40-4.
204. Richtlinien der Bundesärztekammer zur Qualitätssicherung quantitativer laboratoriumsmedizinischer Untersuchungen. *DI Ärztebl* 2008; 105: C301-15.
205. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, et al. Current databases on biological variation: pros, cons and progress. *Scand J Clin Lab Invest* 1999; 59: 491-500.
206. Robinson N, Mangin P, Sangi M. Time and temperature dependent changes in red blood cell analytes used for testing recombinant erythropoietin abuse in sports. *Clin Lab* 2004; 50: 317-23.
207. Rodriguez-Mendizabal M, Lucena MI, Cabello MR, Blanco E, Lopez-Rodriguez B, Sanchez de la Cuesta F. Variations in blood levels of aminoglycosides related to in vitro anticoagulant usage. *Ther Drug Monit* 1998; 20: 88-91.
208. Rosello M, Campos F, Berlanga E, Gavarro A, Acosta A, Torra M. Plasma citrate. An alternative sample for total homocysteine determination. *Clin Chem Lab Med* 2003; 41: S444 (abstract).
209. Roß RS, Eller T, Volbracht L, Paar D. Interferenzen durch Lipämie, Hämolyse und Hyperbilirubinämie am DAX 48-Analysator und ihre klinische Relevanz. *Lab Med* 1994; 18: 233-9.
210. Roß RS, Paar D. Analytisch und klinisch relevante Interferenzen in der Gerinnungsanalytik am Beispiel des MDA 180. *J Lab Med* 1998; 22: 90-4.
211. Rothe G. „Immunphänotypisierung von Leukozyten und Lymphomen“ und „Thrombozytenfunktion (durchflusszytometrisch)“ in Guder WG, Nolte J. Das Laborbuch für Klinik und Praxis. 2. Auflage, München: Elsevier, Urban und Fischer, 2009
212. Russell D, Henley R. The stability of parathyroid hormones in blood and serum samples at 4 °C and at room temperature. *Ann Clin Biochem* 1995; 32: 216-7.
213. Saehse C, Baudach A, Tille D, Avenarius HJ, Heller S, Ruby C, et al. Multicentre evaluation of the Cobas Argos blood cell counter. *J Lab Med* 1994; 18: 441-9.
214. Sakurai S, Shiojima I, Tanigawa T, Nakahara K. Aminoglycosides prevent and dissociate the aggregation of platelets in patients with EDTA-dependent pseudothrombocytopenia. *Br J Haem* 1997; 99: 817-23.
215. Sanders GTB. Sample quality. *Klin Chem Mitt* 1992; 23: 11-8.
216. Schiele F, Vincent-Viry M, Herbeth B, Visvikis A, Siest G. Effect of short- or long-term storage on human serum and recombinant apolipoprotein E concentration. *Clin Chem Lab Med* 2000; 38: 525-8.
217. Schmitt UM, Stieber P, Pahl H, Reinmiedl J, Faleh-Moghadam A. Stabilität tumorassoziierter Antigene in Vollblut und Serum. *J Lab Med* 2000; 24: 475.
218. Schmitt Y. Influence of preanalytical factors on the atomic absorption spectrometry determination of trace elements in biological samples. *J Trace Elem Electrolytes Health Dis* 1987; 1: 107-14.
219. Schmitz G, Rothe G, Ruf A, Barloge S, Tschöpe D, Clemenson KJ et al. European working group on clinical cell analysis: Consensus protocol for the flow cytometric characterization of platelet function. *Thrombos Hemostas* 1998; 79: 885-96.
220. Schoenmakers CHH, Kuller T, Lindemans J, Blijenberg BG. Automated enzymatic methods for creatinine measurement with special attention to bilirubin interference. *Eur J Clin Chem Clin Biochem* 1993; 31: 861-8.
221. Scholer A, von Rickenbach R, Faffa G, Vetter B. Evaluation of a microparticle enzyme immunoassay for the measurement of sirolimus in whole blood (Abbott IMX Sirolimus). *Clin Lab* 2006; 52: 325-34.
222. Schreiber W, Rausch S, Lammers M. Choice of specimen for immunonephelometric protein assays. *Clin Chim Acta* 2005; 355 suppl. 407 (abstract).
223. Schwinger R, Antoni DH, Guder WG. Simultaneous determination of magnesium and potassium in lymphocytes, erythrocytes and thrombocytes. *J Trace Elem Electrolytes Health Dis* 1987; 1: 88-98.
224. Seitz G, Stieckel F, Fiehn W, Werle E, Simonowski UA, Seitz HK. Kohlenhydrat-defizientes Transferrin. Ein neuer, hochspezifischer Marker für chronischen Alkoholkonsum. *DI Med Wschr* 1995; 120: 391-5.
225. Semjonow A. PSA - unverzichtbar in der Urologie. *Diagnostica Dialog* 1994; 3: 3-4.
226. Serio F, Ruggieri V, Varraso L, DeSario R, Mastroianni A, Pansini N. Analytical evaluation of the Dade Behring Dimension RXL N-terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010. *Clin Chem Lab Med* 2005; 43: 1263-73.
227. Sharma A, Anderson K, Baker JW. Flocculation of serum lipoproteins with cyclodextrin. Application to assay of hyperlipidemic serum. *Clin Chem* 1990; 36: 529-32.

228. Shih J, Datwyler SA, HSU SC, Matias MS, Pacenti DP, Lueders C et al. Effect of collection tube type and preanalytical handling on lipoperoxidase concentrations. *Clin Chem* 2008; 54: 1076-9.
229. Siest G, Bertrand P, Quin B, Herbeth B, Serot JM, Masana L, et al. Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. *Clin Chem Lab Med* 2000; 38: 721-30.
230. Simó JM, Camps J, Vilélla E, Gómez F, Paul A, Joven J. Instability of lipoprotein(a) in plasma stored at -70 °C: Effects of concentration, apolipoprotein(a) genotype, and donor cardiovascular disease. *Clin Chem* 2001; 47: 1673-8.
231. Skopp G, Klingmann A, Pölsch L, Matern R. In vitro stability of cocaine in whole blood and plasma including ecgonine as a target analyte. *Ther Drug Monit* 2001; 23: 174-81.
232. Skopp G, Pölsch L, Klingmann A, Matern R. Stability of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in fresh blood and plasma and post mortem blood samples. *J Anal Toxicol* 2001; 25: 2-7.
233. Smith AC, Wu AH. Analytical performance evaluation of the Bayer Advia Centaur BNP immunoassay. *Clin Chem* 2003; 49: A71 (abstract).
234. Smith LJ, Long J, Maters DJ, Carr-Smith HD, Bradwell AR. Sample storage and stability for free light chain assays. *Clin Chem* 2003; 49: A05 (abstract).
235. Smoller BA, Kruskal MS. Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements. *N Engl J Med* 1986; 314: 1233-5.
236. Sokoll LJ, Baum H, Collison PO, Gurr E, Haass M, Luthe H et al. Multicenter analytical performance evaluation of the electrolyte proBNP method. *Clin Chem Lab Med* 2004; 42: 965-72.
237. Solórzanos G, Schiøler V, Nielsen D, Skovgaard T, Dombrowsky P. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. *Clin Chem* 1993; 39: 2077-83.
238. Sonntag O. Haemolysis as an interference factor in clinical chemistry. *J Clin Chem Clin Biochem* 1986; 24: 127-39.
239. Sonntag O, Römer M, Hoackel R. Interferences. In: Haackel R (ed). *Evaluation Methods in Laboratory Medicine*. Weinheim VCH 1993; 101-16.
240. Sonntag O, Glick MR. Serum-Index und Interferogramm – Ein neuer Weg zur Prüfung und Darstellung von Interferenzen durch Serumchromatographie. *Laboratoriumsmedizin* 1989; 13: 77-82.
241. Spain MA, Wu AHB. Bilirubin interference with determination of uric acid, cholesterol, and triglycerides in commercial peroxidase-coupled assays. *Clin Chem* 1986; 32: 518-21.
242. Spence N. Differential leucocyte analysis of samples up to 48h old: improved results with citrate pyridoxal phosphate anticoagulant. *Br J Biochem Sci* 1993; 20: 645-63.
243. Stanger O, Hermann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. Consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thromboembolic diseases: guidelines and recommendations. www.dach-liga-homocystein.org
244. Steimer W. Besondere Bedeutung der Präanalytik und Interpretation bei der Bestimmung von Arzneimittelkonzentrationen. *Der Bay Int* 2004; 24: 147-57.
245. Steinbach G, Rau B, Debard A-L, Javarez J-F, Bienvenu J, Panzio A et al. Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor®-system. *Clin Chem Lab Med* 2004; 42: 440-9.
246. Sliber P. „Malignes Wachstum“ in Guder WG, Nolte J (Hrsg.) *Das Laborbuch für Klinik und Praxis*. 2. Aufl. München: Elsevier, Urban und Fischer, 2009.
247. Slegler H, Fischer Y, Vazquez-Jimenez JF, Graf J, Filzmaier K, Fausten B, et al. Lower cardiac troponin T and I results in heparin-plasma than serum. *Clin Chem* 2000; 46: 1338-44.
248. Szasz G, Gerhardt W, Gruber W, Bernl E. Creatinkinase in serum: 2. Interference of adenylate kinase with the assay. *Clin Chem* 1976; 22: 1806-11.
249. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. *Diabetes Care* 1995; 18: 440-7.
250. Tencer J, Thysell H, Andersson K, Grubb A. Stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain immunoreactivity, orosomucoid and alpha-1-antitrypsin in urine stored at various conditions. *Scand J Clin Lab Invest* 1994; 54: 199-206.
251. Tencer J, Thysell H, Andersson K, Grubb A. Long-term stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain immunoreactivity, orosomucoid and alpha-1-antitrypsin in urine stored at -20 °C. *Scand J Urol Nephrol* 1997; 31: 67-72.
252. Thiery J, Fiedler GM. Der "fehlerhafte" Befund. 2: Häufige Ursachen von Fehlinterpretationen labormedizinischer Befunde. *Internist* 2004; 45: 437-54.
253. Thomas L (ed.). *Clinical Laboratory Diagnosis*. Frankfurt: TH-Books, 1998; Labor und Diagnose, 7th ed. Frankfurt TH-Books, 2008.
254. Tietz NW. *Clinical Guide to Laboratory Tests*, 3rd ed. Philadelphia: Saunders, 1995.
255. Tietz NW. *Textbook of Clinical Chemistry*. Philadelphia: Saunders 1986, 1534-6.
256. Töpfer G, Funke U, Schulze M, Lutze G, Zierns S, Siegert G. Determination of coagulation parameters in citrated venous blood, catheter blood, and capillary blood: preanalytical problems. *J Lab Med* 2000; 24: 514-20.
257. Töpfer G, Hammer T, Seifert A. Einfluß der Lagerungsbedingungen und der Lagerzeit auf die Ergebnisse der CAF-Elektrophorese mit Laktilapuffer. *Zentralbl Pathol* 1983; 122: 1045-51.
258. Töpfer G, Hornig F, Sauer K, Zawta B. Untersuchungen zur Stabilität von 11 Serumproteinen bei Bestimmung mit Immunurbidimetrie. *J Lab Med* 2000; 24: 118-25.
259. Töpfer G, Lindhoff-Last E, Bauersachs R, Funke U, Schulze M, Friedel G et al. Die Beeinflussung von Gerinnungsfaktoren durch rekombinantes Hirudin. *J Lab Med* 2000; 24: 407-13.
260. Töpfer G, Lutze G, Sauer K, Friedel G, Hornig F, Kühnert T, et al. Einfluß der Citratkonzentration in Blutentnahmeröhrchen auf hämostaseologische Meßgrößen. *J Lab Med* 2000; 24: 162-8.
261. Töpfer G, Lutze G, Schmidt LH, Friedel G, Seifert A, Novy EM, et al. Haltbarkeit des Ristocetin-Cofaktors und des Faktor VIII-assoziierten Antigens in Abhängigkeit von den Lagerungsbedingungen. *Z Med Lab Diagn* 1983; 24: 463-8.
262. Tryding N, Tufvesson C, Sonntag O. Drug effects in clinical chemistry, 7th ed. Stockholm: Apoleksbolaget AB, 1996.
263. Tsui NBY, Enders KONG, Lo YMD. Stability of endogenous and added RNA in blood specimen, serum and plasma. *Clin Chem* 2002; 48: 1647-53.
264. Tsuji T, Masuda H, Imagawa K, Haraiawa M, Shibata K, Kono M, et al. Stability of human natriuretic peptide in blood samples. *Clin Chim Acta* 1994; 225: 171-7.
265. Uges Dra (ed.). *Orientierende Angaben zu therapeutischen und toxischen Konzentrationen von Arzneimitteln und Giften in Blut, Serum oder Urin*. DFG Mittl XV der Senatskommission für klinisch-toxikologische Analytik. Weinheim: VCH Verlagsgesellschaft, 1990.
266. Vandamme AM, Van Laethem K, Schmit JC, van Wijngaerden E, Reynders M, Debysse Z, et al. Long-term stability of human immunodeficiency virus, viral load and infectivity in whole blood. *Eur J Clin Invest* 1999; 29: 445-52.
267. Van der Woerd-de Lange JA, Guder WG, Schleicher E, Paetzke I, Schleithoff M et al. Studies on the interference by haemoglobin in the determination of bilirubin. *J Clin Chem Clin Biochem* 1983; 21: 437-43.
268. Van Lenle F, Marchand A, Galen RS. Evaluation of a nephelometric assay for haaptoglobin and its clinical usefulness. *Clin Chem* 1979; 25: 2007-10.
269. Verheest J, Van den Broecke E, Van Meerbeek J, De Backer W, Blockx P, Vermeire P. Calculation of half-life of carcinoembryonic antigen after lung tumor resection. A case report. *Eur Respir J* 1991; 4: 374-6.
270. Visvikis S, Schlenck, Maurice M. DNA extraction and stability for epidemiological studies. *Clin Chem Lab Med* 1998; 36: 551-5.
271. Voit R. Plasma-Serum-Unterschiede und Lagerungsstabilität klinisch-chemischer Meßgrößen bei Verwendung von Plasmatrennröhrchen. Dissertation München: Ludwig-Maximilians-Universität, 1993.
272. Wallace AM. Measurement of leptin and leptin binding in the human circulation. *Ann Clin Biochem* 2000; 37: 244-52.
273. Waine AJ, James IT, Perrel D. The stability of pyridinium crosslinks in urine and serum. *Clin Chim Acta* 1995; 240: 95-7.
274. Warner A, Annesley T. Guidelines for therapeutic drug monitoring services. *Natl Acad Clin Biochem* 1999.
275. Weidemann G, Degel F, Heppner HJ. Der Vergiftungsverdacht. In: Guder WG, Nolte J (eds), *Das Laborbuch für Klinik und Praxis*, 2. Auflage. München: Elsevier Urban und Fischer 2009.
- 275a. Wielders JPM, Wijnberg FA. Preanalytical stability of 25 (OH)-Vitamin D3 in human blood or serum at room temperature: solid as a rock. *Clin Chem* 2009; 55: 1584-5.
276. Wilding P, Zilva JA, Wilde CE. Transport of specimens for clinical chemistry analysis. *Ann Clin Biochem* 1977; 14: 301-6.
277. Willems HPJ, Bos GMJ, Gerrits WBJ, Heijer M, Vloet S, Blom HJ. Acidic citrate stabilizes blood samples for assay of total homocysteine. *Clin Chem* 1998; 44: 342-4.
278. Willemsen JJ, Ross HA, Lenders JWM, Sweep FCG. Stability of urinary fractionated metanephrines and catecholamines during collection, shipment and storage of samples. *Clin Chem* 2007; 53: 268-72.
279. Wisser H. Einflußgrößen und Störgrößen. In: Greiling H, Gressner A (eds.) *Lehrbuch der Klinischen Chemie und Pathobiochemie*, 3rd ed. Stuttgart, New York: Schattauer, 1995; 50-71.
280. Wisser D, van Ackern K, Knoll E, Wisser H, Bertsch T. Blood loss from laboratory tests. *Clin Chem* 2003; 49: 1651-55.
281. Wilthold W. Monitoring of bone turnover. Biological, preanalytical and technical criteria in the assessment of biochemical markers. *Eur J Clin Chem Clin Biochem* 1996; 34: 785-99.
282. Witt I, Beeser H, Müller-Berghaus G. Minimalanforderungen zur Gewinnung von Citratplasma für hämostaseologische Analysen. *J Lab Med* 1995; 19: 245-7.
283. Wolthuis A, Peek D, Scholten R, Moreira P, Gawryl M, Clark T, Westerhuis L. Effect of the haemoglobin-based oxygen carrier HBOC-201 on laboratory instrumentation: Cobas Integra, Chiron blood gas analyzer 840, SysmexTM SE-9000 and BCT. *Clin Chem Lab Med* 1999; 37: 71-6.
284. Woodrum D, French C, Sharnel LB. Stability of free prostatic-specific antigen in serum samples under a variety of sample collection and storage conditions. *Urology* 1996; 48 (suppl): 33-9.
285. Woodrum D, York L. Two-year stability of free and total PSA in frozen serum samples. *Urology* 1998; 52: 247-51.
286. Wu AHB, Laios I, Green S, Gornel TG, Wong SS, Parnley L, et al. Immunoassays for serum and urine myoglobin: myoglobin clearance assessed as a risk factor for acute renal failure. *Clin Chem* 1994; 40: 796-802.
287. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR, et al. Plasma homocyst(e)line as a risk factor for early familial coronary artery disease. *Clin Chem* 1994; 40: 552-61.
288. Young DS. Effects of drugs on clinical laboratory tests, 5th ed. Washington: AACC Press, 2000.
289. Young DS. Effects of preanalytical variables on clinical laboratory tests, 3rd ed. Washington: AACC Press, 2007.
290. Zawta B, Weisheit R. Serum or plasma - pros and cons. *Clin Chem Lab Med* 2003; 41, Suppl: 363 (abstract).
291. Zhang DJ, Elswick RK, Miller WG, Bailly JL. Effect of serum-contact time on clinical chemistry laboratory results. *Clin Chem* 1998; 44: 1325-33.
292. Zürcher M, Sulzer I, Barizzi G, Lämmle B, Alberio L. Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature. *Thromb Haemost* 2008; 99: 416-26.

Notice

specimencare.com

A Useful Preanalytical Resource Centre Sponsored by BD



BD Diagnostics
Preanalytical Systems

BD, BD logo and all other BD trademarks
are property of Becton, Dickinson and
Company. © 2010 BD.
All other brands are trademarks of their
respective owner.

The Danby Building
Edmund Halley Road
Oxford Science Park
Oxford
Ox44DQ
U.K.
www.bd.com